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Abstract 
 
Candida albicans is an opportunistic fungal pathogen. It is the fourth leading cause of 
nosocomial infections and can endanger immunocompromised patients. Candida has the ability 
to form biofilms on plastic medical devices, such as catheters and central nervous system shunts. 
Two clinical isolate series were profiled using a number of phenotyping assays comprising in 
vivo, ex vivo, and in vitro tests. These tests shed light on host-pathogen relations as well as offer 
potential information useful in the treatment of these infections. Fluconazole, an antifungal, is 
the first line of treatment for fungal infections. The incidence of fluconazole-resistant infections 
is increasing annually, and there are not many other drugs available to treat infections. In 2013, 
Fazly et al. discovered the drug Filastatin, which prevents adhesion and filamentation of 
Candida albicans. In our study, two screens were performed to identify the target of Filastatin. 
Because there is no complete knockout library for Candida, an available, partial knockout library 
was screened. This library is enriched for transcription factors. We screened for regulators of 
biological pathways that may be important for adhesion and filamentation in Candida albicans, 
to identify potential Filastatin targets. The iron-uptake pathway was chosen as the focus for the 
remainder of this study.   
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Chapter 1: An Introduction to Candida albicans 
Candida albicans 
Fungi are ubiquitous and can grow in the mucous membranes, intestinal tracts, and on the skin. 
They are also found in the soil and on plants, trees, and other vegetation. Although not all fungi 
are pathogenic, some can cause serious disease and pose a significant public health risk. Within 
the last three decades, fungi have been identified as the leading cause of nosocomial infections 
(Pfaller, 2007; Prevention, 2014c) especially among immunocompromised patients. 
Yeasts that belong to the genus Candida can cause both superficial and invasive infections. 
Superficial infections include oropharyngeal infection or “thrush,” vaginitis (commonly called 
“yeast infection”), and diaper rash. While superficial infections are often persistent, they are 
usually not life threatening. However, when Candida invades the bloodstream, the infection 
becomes systemic and is often deadly (Control, 2013; Prevention, 2014b). Fungi in the Candida 
genus have emerged as major human pathogens, becoming the fourth leading cause of 
bloodstream infections (BSI) in hospitals around the United States, with 7,000–28,000 annual 
reports of Candida specific BSIs (Pfaller, 2007). Some strains, specifically C. albicans, are 
becoming increasingly resistant to conventional antifungal treatments (Pfaller, 2007). For 
example, in 2013 the United States Center for Disease Control (CDC) reported that fluconazole 
resistant Candida albicans poses a serious threat and is responsible for approximately 3,400 
cases annually, including those that are superficial as well as those in the bloodstream (Control, 
2013). The lifestyle and virulence strategies used by C. albicans are the subject of intense 
research (Pfaller, 2007). A BSI often begins with a biofilm on medical devices, such as dental 
implants, catheters, heart valves, bypass grafts, ocular lenses, artificial joints, and central 
nervous system (CNS) shunts (Prevention, 2014c). In persons whose gastrointestinal tract is 
heavily colonized by C. albicans, it is thought to invade the epithelium in the villi and cross into 
the bloodstream. The most common non-albicans infections seen are caused by the emerging 
opportunistic pathogens C. parapsilosis, C. tropicalis, and C. glabrata. 
Candida parapsilosis is also capable of forming biofilms on catheters, which can lead to 
systemic infection if the catheter is placed before removing the yeast (Prevention, 2014c). 
Candida glabrata, evolutionarily a distant relative of C. albicans, was once considered 
nonpathogenic (Prevention, 2014c). With the increasing incidence of AIDS and corresponding 
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rise in the use of immunosuppressive agents, C. glabrata infections have also increased as the 
second most common causative agent of superficial and systemic Candida infections. It is often 
difficult to treat because it is resistant to many azole antifungal agents (Fidel, 1999). Candida 
tropicalis is the fourth most common species of the Candida genus (Pfaller, 2007). It is 
common among patients with hematologic malignancies. It is sensitive to azole drugs and other 
antifungal agents, which have decreased the incidence of C. tropicalis within the United States. 
However, worldwide, its incidence continues to rise, which makes it a candidate for study 
(Pfaller, 2007). 
Animal Models 
Several animal hosts have been used to study fungi that cause these common infections (Figure 
1). Each model has its limitations, but can also yield useful information. Therefore, it is crucial 
that researchers choose an appropriate model best suited to address the experimental hypothesis 
being tested. The most common host systems are mice, zebrafish larvae, fruit flies, and 
nematodes. Clinical isolates, from human infections, can provide useful tools, which are often 
studied using in vivo, ex vivo, and in vitro techniques. Mice are considered the “gold standard” 
for studying infection because of its direct implication for human systems. The mouse has been 
used to model oral, vaginal, and systemic infections that have been shown to mimic human 
infection (Conti, 2009; Fidel, 1996; Takakura, 2003). While this system has many benefits, 
there are several limitations associated with this study. These limitations include ethical 
concerns, small sample size, expensive handling, and a laborious knockout process. Therefore 
in this study, C. elegans is the in vivo model used to study C. albicans infections.  
Caenorhabditis elegans 
Caenorhabditis elegans has been used extensively as a model system to study various biological 
phenomena due to many positive aspects including a rapid lifecycle, its completely sequenced 
genome, genetically identical progeny (due to self-fertilization), and a transparent cuticle that 
facilitates whole animal microscopy (Stiernagle, 2006). More recently, it has been used as an 
animal model for the study of infectious disease (Ewbank, 2002; Garsin et al., 2003; Hodgkin, 
2000; Jain, 2013). Nematodes are exposed to the infectious agent in their diet, therefore 
multiplicity of infection is not easily determined (Mylonakis, 2002). Fungi concentrate distally 
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to the pharyngeal grinder and infected worms show a distended gastrointestinal system (Jain, 
2013; Jain et al., 2009; Mylonakis, 2002). 
Caenorhabditis elegans has been a host model for many gram-positive and gram-negative 
bacterial infections such as Salmonella typhimurium, Pseudomonas aeruginosa, and 
Staphylococcus aureus.  Certain long-lived C. elegans mutants show immunity to these 
bacterial infections (Mahajan-Miklos, 1999). Recently, C. elegans was used as a host to study 
fungal diseases, but more importantly, discoveries made in worms recapitulate virulence 
patterns in mouse and human infection (Mylonakis, 2002). For example, several virulence 
genes, including protein kinase A (PKA), protein kinase R (PKR), and G-protein alpha (GPA) 
were first identified in C. neoformans, which modulates virulence in C. elegans (Mylonakis et 
al., 2004). These same genes were later shown to be important for Cryptococcus infection in 
mammals (Mylonakis, 2002). Disrupting PKA increases virulence of C. neoformans in mice 
(D'Souza et al., 2001), a phenomenon that was replicated in C. elegans.  
Infected nematodes show a deformity in the post-anal region (Dieterich et al.), which is 
visible four- to five-days post-infection (Hodgkin, 2000; Jain, 2013). Other disease markers 
such as swelling in the vulvar region and intestinal distension have been reported for both 
fungal and bacterial infections (Hodgkin, 2000; Jain, 2013). Ingestion of yeast can be 
microscopically monitored over time using fluorescently marked C. albicans (Jain, 2013), 
confirming that accumulation of fungi is the likely cause of intestinal distension. 
These disease markers can be used to study the progression of disease, while survival assays 
provide a quantitative measure of disease and death. As a simple starting model, C. elegans is a 
quick and inexpensive way to study virulence of many fungal species. However, the results 
often need to be verified in a mammalian system, like mice. 
The nematode is a convenient model to study innate immunity, since facets of it are 
conserved in humans (Jain, 2013; Jain et al., 2009) and host genes can be easily modulated via 
RNAi (Kim and Rossi, 2008). Furthermore, infections do not require handling of animals, and 
therefore, can be performed in a high throughput fashion. Another advantage is that worms can 
be frozen (indefinitely) and thus do not require maintenance of live cultures. 
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Figure 1: Model Systems Used to Study Fungal Infections, like C. albicans 
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Ex Vivo Systems 
Ex vivo systems for studying fungal infections include phagocytes in culture and tissue explants, 
as shown in Figure 1. Phagocytes are our primary defense against fungal pathogens. 
Macrophages and neutrophils play a central role in antifungal immunity by ingesting and killing 
pathogens (Lo, 1997; Lorenz and Fink, 2001; Rubin-Bejerano et al., 2003; Wheeler and Fink, 
2006). They are also responsible for initiating adaptive immune responses. 
Cultured macrophages can include both primary and immortalized cells. Immortalized cell 
lines such as the RAW264.7 and J774 are robust and can withstand harsh treatments to remove 
these adherent cells from surfaces, such as trypsinization and scraping, while still proliferating. 
Immortalized macrophages have been instrumental in uncovering aspects of Candida virulence 
such as hyphae formation, extracellular lipase, and proteinase production (Németh, 2013). 
However, the multiple passages and harsh growth and handling conditions of immortalized 
macrophages specifically select them to be more robust at the expense of other properties that 
might be important for immunity. Therefore, primary macrophages are considered better for 
studying immunity than immortalized macrophages even though they are more difficult to extract 
and maintain (Németh, 2013). 
Németh and others (2013) infected both immortalized murine macrophage and primary 
human macrophage hosts with Candida parapsilosisis in the paper “Characterization of 
Virulence Properties in the C. parapsilosis Sensu Lato Species” (Németh, 2013). The fungi 
exhibited varying degrees of virulence when exposed to each type of macrophage (Németh, 
2013). C. parapsilosis exhibited the highest resistance to killing by primary human 
macrophages, compared to C. orthopsilosis and C. metapsilosis. However, this difference was 
not reflected in the murine virulence model. In spite of these differences, cultured cell lines are 
useful and can complement live, whole-animal studies. 
Transcriptional profiling of C. albicans within phagosomes has been performed (Thewes, 
2007). Strains have been shown to quickly adapt and alter their transcriptional profile in many 
circumstances related to infection, such as response to stress, iron deprivation, and interaction 
with macrophages. In order to understand Candida infection, Thewes and others (2007) used in 
vivo and ex vivo techniques to understand the genes associated with infection in parenchymal 
organs (e.g., the liver). An ex vivo tissue explant of porcine liver-infected tissue was shown to 
mimic murine model of in vivo infection. Candida albicans was directly injected into both mice 
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and pig livers. Ex vivo tissue explants from both exhibited a similar extent of deep-tissue 
invasion (Thewes, 2007). Excised murine vaginal mucosal tissue is also used as a substrate to 
study vaginal infections (Harriott et al., 2010). These ex vivo systems provide a simple and rapid 
method for optimizing conditions prior to in vivo assays (Fazly et al., 2013). 
In Vitro Systems 
Viewing a fungal phenotype on an agar plate is a “host-free” method to study fungal virulence. 
For example, C. albicans mutants such as efg1−/− and cph1−/− showed reduced hyphal growth 
on agar media, and the double knockout efg1−/− cph1−/− does not form hyphae under most in 
vitro conditions. This double knockout mutant was later shown to be avirulent in a murine 
model, which linked hyphal growth and virulence (Lo, 1997). Since then, many mutants with 
defects in dimorphic transition have been shown to be attenuated in virulence. This efg1−/− 
cph1−/− double mutant has been used extensively to validate other host models (Brothers, 2011; 
Jain, 2013). 
Chemical sensitivity in vitro can be used as a proxy for pathways that are important in vivo. 
Fungal response to important aspects of the human innate immune system such as reactive 
oxygen species can be mimicked in vitro using menadione and hydrogen peroxide (Homann, 
2009). Cell wall stressors such as sodium dodecyl sulfate (SDS), caffeine, and calcofluor 
(Homann, 2009) have been used in vitro to study the effects on the cell wall. Since human cells 
do not possess cell walls, they are good targets for drugs, like capsofungin (Homann, 2009). 
Other drug sensitivity assays can be modeled in vitro by plating fungi on drug-infused plates 
(Homann, 2009). The role of metals can be mimicked in vitro by using scavengers or chelators 
in vitro. For example, the C. albicans transcription factor Hap43 is activated by iron deficiency 
in vivo (Hsu et al., 2011) and is also required for growth upon iron-deprivation in vitro (Baek et 
al., 2008; Homann, 2009; Hsu et al., 2011). Hap43 also regulates virulence, and mice infected 
with hap43−/− strains showed attenuated virulence (Baek et al., 2008). The pathways regulating 
iron homeostasis are complicated, but in vitro techniques may be used to fine tune regulatory 
networks. 
In vitro models can also be used to study reconstituted epithelial cells in order to model 
human infection (Figure 1). The role of certain virulence-related genes in fungal infection can 
first be modeled in vitro on reconstituted epithelial cells before using more expensive in vivo 
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models. For example, the secreted aspartyl proteinases (SAP) of C. albicans have been linked to 
virulence in mucosal infection in clinical isolates of patients with chronic vaginitis (Schaller, 
2003). This family of 10 enzymes was first studied using reconstituted vaginal epithelial cells in 
order to link them to epithelial damage that occurs during disease. The 10 SAP genes are 
differentially expressed during infection. Specifically, SAP1, SAP6, SAP9, and SAP10 showed a 
stronger signal in conjunction with mucosal lesions (Schaller, 2003). These SAP genes showed 
strong signals in both in vitro models as well as in vivo samples from patients with vaginal 
infections. These lesions showed severe damage in the epithelial cells including: edema, 
vacuolization, and detachment of keratinocytes. Differential SAP expression has also been 
linked to “thrush” infections (Schaller, 2003). Despite this, they are not identical to those 
present in vaginal infections (Schaller, 2003). 
Biofilm formation is a virulence determinant that is well suited to study in a host-free 
environment. Biofilms are typically made up of multiple microbial communities that stick to 
each other and also abiotic surfaces (Hogan et al., 2004; O'Toole et al., 2000). The microbes 
secrete extracellular materials (Chandra, 2001) and are important in the context of infection 
because they are drug resistant. For example, C. albicans is thought to gain access to the 
bloodstream via plastic devices such as central lines, catheters, or other implanted devices. The 
mortality rate for patients with catheter-related BSI is approximately 41 percent (Chandra, 
2001). Biofilm associated cells have shown resistance to antimicrobial therapies as well as 
phagocytes and antibodies (Li et al., 2012).  
As shown in Figure 2, formation of biofilm proceeds in four stages. During the first stage, 
the fungal communities attach to the surface, grow, and aggregate. The second stage is thought of 
as irreversible attachment. The third is characterized by filamentation of the yeast cells. Finally, in 
the last stage an extracellular matrix, a predominantly noncellular material, covers fungal 
microcolonies and is secreted into the milieu (Chandra, 2001). Biofilm formation plays a role in 
resistance to antifungal drugs, which can be explained by several factors. These factors include 
the effect of the biofilm matrix on penetration of the drugs, the decreased growth rate and 
nutrient limitation characterized by the biofilm, the expression of the resistance genes, and the 
presence of “persister” cells (Douglas, 2003).  
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Figure 2: Stages of Biofilm Formation. The first stage (a) initial attachment takes between 0 and 4 hours; the 
second, (b) irreversible attachment, between 4 and 10; filamentation (c) after 10 hours; the last stage (d) 
biofilm formation, takes more than 24 hours (Joseph Heitman, 2006a).  
In vitro systems are extensively used to study fungal virulence to get mechanistic clues, but 
often have to be validated in an animal model to account for the complex biology in the host 
environment. Each of these systems is used to study Candida with the hope of finding better 
methods to treat infections.  
Available Drugs 
Several antifungals are available on the market to treat C. albicans infections. There are four 
types of available antifungal drugs: polyenes, nucleic acid synthesis inhibitors, echinocandins, 
and ergosterol biosynthesis inhibitors (EBI). The most popular are the azole drugs, but the 
known mechanism of each will be discussed briefly.  
Polyenes, like amphotericin B (AmB) and nystatin, target ergosterol in fungal membranes. 
They work by binding to ergosterol and creating pores to allow molecules to diffuse across the 
membrane, which results in cell death. AmB is used for severe systemic infections, especially 
when rapid response is needed. However, like many drugs, in high doses, AmB is associated 
with nephrotoxicity (Joseph Heitman, 2006b).  
Fungi and plants are able to convert 5-Flucytosine (5FC), the available nucleic acid inhibitor, 
into 5-fluorouracil, which is then incorporated into the DNA and RNA. Mammals do not 
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possess the cytosine deaminase that performs this conversion, which makes this drug fungal 
specific. However, there is a high incidence of resistance to this drug (Sheikh et al., 2013).  
Echinocandins are the newest drugs available to treat fungal infections. They work to inhibit 
β-1,3-glucan synthase, which is responsible for the production of the glucan component of the 
cell wall. There are several strains developing resistance to this class of drugs as well (Beyda et 
al., 2012).   
Azoles are the most popular EBI antifungal agents, which work to inhibit the synthesis of 
ergosterol. When fungi lack ergosterol in the plasma membrane, this results in the loss of the 
plasma membrane function and fluidity, which inhibits cell growth (Taff et al., 2012). 
Fluconazole, an azole drug, is usually the first line of defense for treatment. Resistance is also 
developing to this popular drug. There are roughly 3,400 Fluconazole-resistant Candida 
albicans infections annually. Thus there is a demand for new drugs.  
Biofilm formation can provide up to 1,000-fold more resistance to antifungal drugs, even 
without the presence of genetic markers that are known to provide resistance (Ramage et al., 
2005). Potential drugs could therefore 1) target the components of the biofilm (Taff et al., 2012) 
or 2) prevent biofilm formation (Fazly et al., 2013).  
A Potential Drug: Filastatin 
In 2013, the Rao and Kaufman labs performed a screen of the Chembridge Chemical library of 
30,000 small-molecule compounds to identify new compounds that prevent Candida albicans 
adhesion to plastics. Adhesion is the first step in biofilm formation (Figure 2). In this screen, the 
mutant edt1 −/− was used as a positive control for poor adhesion because it lacks a cell wall 
adhesion protein (Fazly et al., 2013). The primary screen found 400 compounds (1.3 percent) 
that prevented adhesion by more than 75 percent to the plastics. A second screen was performed 
on the 400 compounds identified from the primary screen in order to rule out phenotypes 
potentially caused by an artifact of the assay used in the first screen. Twenty-six compounds 
were identified from this screen. These 26 compounds were tested in vivo for toxicity and dose 
dependence (Fazly et al., 2013). In addition, structural analysis was performed. The initial 
concentration tested was 50µM, and several of the drugs were ineffective upon reducing the 
concentration to 25µM. One compound, Filastatin, was identified because it prevented adhesion 
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and filamentation, was non-toxic, and performed well at lower concentrations (Fazly et al., 
2013).   
In addition to preventing adhesion to plastics, Filastatin also prevents attachment of Candida 
to human epithelial cells, which may limit virulence. Filastatin also prevents adhesion of other 
Candida species: dubliniensis, tropicalis, and parapsilosis. It has been shown to exhibit 
antifungal activity in C. elegans as well (Fazly et al., 2013). The mechanism of the pathway is 
not yet known and must be identified before it can be used in a clinical setting. One goal of this 
thesis project was to perform a screen of a C. albicans mutant library to find potential targets 
and target pathways of the drug Filastatin. Additionally, once these pathways were identified, 
several experiments were performed to elucidate Filastatin’s role within it. Clinically relevant 
strains, from two patients, were tested to make connections between virulence and adhesion. In 
addition, the strains were tested in C. elegans for virulence and using the ex vivo model, murine 
macrophages. An in vitro profile was created for each of the strains. Finally, a synthesis of host-
pathogen relations and the model systems used to study a wide range of fungal pathogens was 
created to further this field of study.  
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Chapter 2: Finding the Target of Filastatin: A Small-Molecule Inhibitor 
of Candida albicans Adhesion 
Introduction 
Filastatin, a small-molecule that prevents adhesion, was discovered in 2013 using a screen of 
30,000 compounds from a small-molecule library (Fazly et al., 2013). Through toxicity, dose 
dependence, and structural analysis, Filastatin was determined to have potential implications for 
future clinical use to prevent C. albicans biofilm formation. Before Filastatin can be used at the 
bedside, the mechanism of action must be identified. In order to identify the target of a drug, 
normally, a screen of a total knockout library would be preformed. However, there is no total 
knockout library—instead, an available partial library was screened (Noble et al., 2010). Using 
the same adhesion assay performed to discover the drug, two screens were performed on this 
available knockout library to look for potential targets and pathways.  
The iron uptake pathway was identified using this screen. This pathway plays a role in 
virulence as well as adhesion. Candida albicans is able to utilize hemoglobin, which is the 
largest source of iron in the host. Rbt5 is the receptor for acquiring hemoglobin from the 
environment. It dissociates heme from the globin, and a heme oxygenase, Hmx1, degrades 
hemoglobin to α-biliverdin (Butler et al., 2009). Finally, the cell takes up the released iron into 
the cytoplasm (Kornitzer, 2009).  
There are two sources of iron that Candida can utilize, Fe2+ or Fe3+. Hemoglobin is a 64 kDa 
globular protein. Each of the heme groups binds an iron ion in the ferrous form (Fe2+); oxidation 
of the iron yields the ferric form (Fe3+). About 30 percent of the iron available in the human 
body is sequestered in ferritin, as Fe3+. C. albicans is also capable of utilizing ferritin as an iron 
source as well as the ferrous iron from hemoglobin. This method is dependent on cell surface 
adhesion and the protein Als3. An als3 mutant has been shown to have reduced ability to invade 
epithelial cells and is unable to bind ferritin (Kornitzer, 2009), indicating it is vital for this type 
of iron uptake. 
Filastatin could be playing a role in the iron-uptake pathway in several ways: 1) by 
interfering with the cell’s ability to use hemoglobin, 2) by sequestering ferrous or ferric iron and 
preventing the cell from utilizing it, or 3) by interfering with mechanisms downstream to 
prevent adhesion.  
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Materials and Methods 
Adhesion Assay 
For the target screen, single colonies were picked and inoculated into five milliliter cultures of 
Synthetic Complete Media (SC) (Sherman, 1991) + 0.15 percent glucose media and grown 
overnight in a rotating wheel. The optical density (OD) of the cultures was then measured at 
OD600nm. Cultures were spun down and re-suspended in fresh SC + 0.15 percent glucose to a 
final concentration of 0.5 OD/mL. C. albicans strains, 200 µL at 0.5 OD/mL, were pipetted onto 
96-well flat-bottom polystyrene plates. Filastatin or DMSO was added to cultures at appropriate 
concentrations, never exceeding one percent DMSO. Plates were covered with aluminum foil 
and incubated at 37˚C for four hours. After four hours of incubation, plates were decanted, and 
40 µL of 0.5 percent crystal violet (CV) stain was added to each well. The plates were covered 
and left at room temperature to incubate for 45 minutes. Plates were then decanted and washed 
by submersion 10 times in an ice bucket filled with dH20, changing the water every five washes. 
Plates were tapped onto a paper towel to remove residual dH20, and 200 µL of 75 percent 
MeOH was added to each plate and incubated at room temperature for 30 minutes. The plates 
were then read at 590 nM to detect relative absorbance.  
Interaction Assay 
The adhesion assay was performed as outlined above using the wild type strain from the mutant 
knockout library (Noble et al., 2010). Filastatin and hemoglobin were added to the cultures at 
the outlined concentrations. Ferrozine was added in 1 mM concentration (Weissman and 
Kornitzer, 2004) to the SC media prior to resuspending the C. albicans and performing the 
adhesion assay. 
Biofilm Assay (Glass) 
A culture of wild type Candida from the knockout library (Noble et al., 2010) was grown in 
YPD media (Sherman, 1991) overnight at 30˚C. This strain was resuspended at 0.01 OD/mL in 
five milliliters of SC media (Sherman, 1991), containing the appropriate concentrations of 
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Ferrozine, Filastatin, and hemoglobin. Pictures were taken after 24 hours, and the biofilms 
inspected visually.  
Biofilm Assay (Plastic, 96-Well Format) 
The wild type strain from the knockout library (Noble et al., 2010) was grown overnight in YPD 
media and resuspended to a final concentration of 0.01 OD/mL in SC media containing + 0.15 
percent glucose. In a 96-well plate, 200 µL of the Candida was dispensed. Appropriate 
concentrations of the Ferrozine, Filastatin, and hemoglobin were added to the wells. The plates 
were incubated for 20 to 24 hours and then decanted. The CV stain was added and the rest of 
the Adhesion Assay protocol followed. 
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Results 
Two screens were carried out in order to find the target of Filastatin. From these screens, two 
major pathways were identified: filamentation and iron-uptake. We chose to focus our attention 
on the iron-uptake pathway because it has already been shown that Filastatin prevents 
filamentation.  
Initial Screen 
For the original hypothesis, shown in Figure 3, it was postulated that the mutants that would act 
as the target for the drug would behave like wild type without the drug. The wild type strain 
adheres to plastics, and thus mutants within two standard deviations of wild type adhesion 
would be considered. From these mutants, in the presence of the drug, there would be an 
exaggerated (more than a 25 percent) change in adhesion. This threshold, 25 percent, was set by 
the lab upon viewing the data as a whole. The wild type showed between 10 and 25 percent 
reduction in adhesion, regularly, when the drug was added. Therefore, the exaggerated response, 
compared to wild type, could indicate that there was either a more than 25 percent increase or 
decrease in adhesion.  
 A summary of the results from this screen is shown in Table 1. From the initial screen, 233 
mutants were found, which is about 35 percent of the library and about four percent of the 
genome. There were two mutants, fad3 and orf19.1239, that adhered more than wild type in the 
presence of the drug. In the presence of the drug, the rest, 231 mutants, adhered less than the 
wild type; the list of these genes can be found in Table 1 of Appendix A. 
 The number of mutants found from this screen was a large part of the library, about 35 
percent. Despite the fact that it is only four percent of the genome, the coverage that the library 
provides is only about 12 percent of the genome, meaning it would likely be significantly more 
if the coverage of the library was greater. Gene Ontology (GO) term analysis was used to 
classify genes into relevant pathways. The results showed that many of the genes were involved 
in filamentous growth, cellular response to stimuli, and response to nutrient levels. The fact that 
several of the genes were involved in filamentous growth validates this screen because it is 
known that Filastatin prevents filamentation. The number of genes prevented further useful 
analysis though, so a second, more stringent screen was designed. 
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Figure 3: The Original Hypothesis for the Initial Screen—Targets Would Show an Exaggerated Response t 
Filastatin. Mutants (shown as yellow cells) show a similar level of adhesion to plastic (shown in red) without 
the drug, but in the presence of the drug, they show an exaggerated response. (Figure based on an original 
by R. P. Rao (Rao, 2015c)) 
  
Table 1: Summary of Results from Initial Receptor Screen. There are a significant number of mutants that 
adhere less than wild type (WT). 
Summary of Results: Initial Screen 
Mutants Number of Mutants Percent of Library Percent of Genome 
Adhering more, with 
drug, than WT 
2 0.3% 0.03% 
Adhering less, with 
drug, than WT 
231 34.3% 3.85% 
Second Screen 
Because of the high number of mutants and over-representation of non-descript pathways from 
the first screen, a second screen was performed to narrow down the results. The new hypothesis, 
shown in Figure 4, stated that the target mutants would not be affected by the drug’s presence. 
The mutants were significantly (at least two standard deviations) different from the wild type 
without the drug. When the drug was added, these targets showed a change of less than 10 
percent.  
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Figure 4: The Hypothesis for the Second Screen States—Target Gene Will Show No Response to the Drug. 
Mutant cells, shown in yellow, show a significant difference in adhesion (shown in red) without the drug to 
wild type. However, when the drug was added, the mutants showed no change in adhesion level. (Based on a 
figure produced by R.P. Rao (Rao, 2015a)) 
From this screen, 43 mutants were identified. A summary of the results is shown in Table 2. 
The mutants were screened initially for a different level of adhesion, by at least two standard 
deviations, from the wild type with no drug. These mutants were then screened with the drug, 
looking for a mutant that showed less than a 10 percent change in adhesion. There were 28 
mutants that showed an increase in adhesion compared to wild type with no drug, and 15 
mutants that showed a decrease in adhesion compared to wild type. These mutants showed less 
than a 10 percent change in adhesion when the drug was added. It was expected that the genes 
represented in this list would code for a protein that would normally act with Filastatin; thus 
when the protein was missing, the mutants would be blind to the addition of the drug.  
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to Filastatin 
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in response to Filastatin 
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Table 2: Summary of Results from Second Target Screen 
Summary of Results 
Mutant Number of Mutants Percent of Library Percent of Genome 
Mutants that adhere 
LESS than WT with 
no Filastatin 
28 4.1% 0.4% 
Mutants that adhere 
MORE that WT with 
no Filastatin 
15 2.2% 0.2% 
 
The full list of mutants found from this screen can be found in Tables 1 and 2 of Appendix B. 
GO term analysis was used to classify genes into relevant pathways. Two pathways were over-
represented. The first were genes that regulate adhesion and biofilm formation. This is not 
surprising because the screen was designed to find targets related to adhesion and filamentation. 
The second pathway represented genes involved in iron uptake. It was decided that the focus of 
the rest of this study would be on this pathway. Iron uptake from the bloodstream is essential for 
virulence of C. albicans (Noble, 2013).  
A pathway for iron uptake can be seen in Figure 5. The genes highlighted in this pathway are 
RBT5, PGA10, and PGA7. The mutants, rbt5 and pga10, were identified from the second 
screen. The rest of these mutants, however, were not pulled from this screen due to the small 
coverage of this knockout library. Looking at the other mutants identified from the second 
screen, many were regulated by Hap43, which is a transcription factor that is induced in low-
iron conditions (Hsu et al., 2011) and regulates the process of iron uptake (Noble, 2013). For 
future tests on this pathway the mutants were obtained from another lab and are isogenic strains.  
RBT5 and PGA10 are two redundant genes that code for extracellular structures responsible 
for acquiring hemoglobin and heme from the environment (Weissman and Kornitzer, 2004). 
Pga7 acts intracellularly to shuttle the iron from the hemoglobin across the cell membrane into 
the cytoplasm, where the iron can be extracted. In order to understand how this pathway 
contributes to adhesion and possible interactions with Filastatin, several tests, including Atomic 
Force Microscopy (AFM) (Rosch, 2015) and interaction assays, were performed.  
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Figure 5: Iron-Uptake Pathway Working within the Cell. Rbt5 and Pga10 are extracellular structures, Pga7 
works within the cell, and Hap43 is a transcription factor that regulates the process. Figure produced by R. 
P. Rao (Rao, 2015b). 
Atomic Force Microscopy (AFM) Results 
In order to understand how this iron pathway relates to adhesion, Atomic Force Microscopy 
(AFM) was used. The methods were developed by a group of MQP students, and thus not 
included here (Rosch, 2015). Briefly, the AFM measures the force that the cell applies to a glass 
surface. Each cell was tested on the glass 40 times and the trials were run in triplicate. The 
results (Figure 6) show that the iron mutants, rbt5 and pga10, which are external structures, 
show reduced adhesion forces. The mutant pga7, which acts internally, shows a wild type level 
of adhesion. The mutant, hap43, normally acting as a transcription factor in the pathway, shows 
intermediate adhesion force between low levels and wild type adhesion forces.  
These results show that there is a clear connection between the iron-uptake pathway mutants 
and adhesion, especially of the extracellular structures. Based on this information, it is 
important to know whether Filastatin affects the adhesion forces of the wild type strain. For this 
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reason, the adhesion force of wild type tested on glass and glass treated with Filastatin were 
measured. The results are shown in Figure 7. 
  
Figure 6: AFM Results for Mutants in the Iron-Uptake Pathway. Each mutant was run in triplicate. The 
error bars represent standard deviation (SD). 
 
Figure 7: Adhesion Force Measurements using AFM of Wild Type Strain on Glass and Glass Treated with 
Filastatin. The error bars reflect SD. 
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A student’s t-test was performed on the data, and the results show statistical significance 
between the two conditions (p = 0.037) (Rosch, 2015). This indicates that Filastatin is able to 
reduce the adhesion force of the Candida. Based on the data from the AFM, there may be a 
connection between iron-uptake pathways and adhesion. To understand this interaction, 
especially how Filastatin could be working within this pathway, interaction assays modeling 
adhesion in the presence of Filastatin and hemoglobin were performed.  
Interaction Assays: Hemoglobin and Filastatin 
In order to test the theory that Filastatin may be interacting with the iron-uptake pathway, the 
interaction assay was performed varying the concentration of hemoglobin in the presence of 
constant concentration of Filastatin, as well as the inverse. The results, in Figure 8, suggest that 
there was an interaction between this pathway and Filastatin.  
In Figure 8a, the concentration of Filastatin was held constant at 15 µM, and the level of 
hemoglobin was increased. When only Filastatin was in the system, the level of adhesion 
decreased from a baseline adhesion (no hemoglobin and no Filastatin). As the concentration of 
hemoglobin was increased, levels of adhesion increased. Figure 8b shows that when only 
hemoglobin was added to the system, the level of adhesion increased (compared to baseline), 
then adding Filastatin to the system decreased the adhesion. Figure 1 in Appendix C shows 
another view of the interaction assay when the same concentration of Filastatin and hemoglobin 
are added—the results are not simply additive, as one would suspect. This does, however, 
suggest that there is an interaction between the two.  
Before confirming the interaction between hemoglobin and Filastatin, adhesion assays were 
performed to find the individual effect of both hemoglobin and Filastatin on Candida’s ability 
to adhere to plastics. Figures 9 shows increasing concentrations of Filastatin and hemoglobin, 
respectively. Increasing the concentration of Filastatin shows a steady decrease in adhesion, 
while increasing the concentration of hemoglobin shows a steady increase in adhesion. Both 
curves show a plateau at the same concentration, 10 µM, indicating that if this is a surface 
phenomenon, then Candida’s receptors may have been saturated. Otherwise, the maximal effect 
of altered adhesion occurs at the same concentration, 10 µM, which may indicate that the two 
compounds are vying for a similar receptor.  
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Figure 8: Interaction Assay Results for the Wild Type Strain. In both Panel a and b, the first well has no 
hemoglobin or Filastatin added, thus it is baseline adhesion. Panel a) shows a constant concentration of 
Filastatin (15 µM) in the last four wells, with increasing concentration of hemoglobin (0–50µM). Panel b) 
shows a constant concentration of hemoglobin (5 µM) with increasing concentrations of Filastatin (0–50µM).  
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Figure 9: Wild Type Strain in the Presence of Increasing Concentration of Filastatin (0–50µM) and 
Hemoglobin (0–50µM) 
 
These results suggest that Filastatin may be acting within the iron-uptake pathway to affect 
adhesion. In order to mimic the low iron conditions of the bloodstream, the effects of two iron 
chelators, bathophenanthrolinedisulfonic acid (BPS) and Ferrozine, were tested in the 
interaction assay (Figure 10). Both chelators produce a color change when bound to iron. BPS 
chelates extracellular iron, Fe3+, while Ferrozine is known to chelate Fe2+, which occurs 
intracellularly. The Ferrozine is capable of binding to the iron in hemoglobin. BPS shows no 
real effect on the interaction assay, as the increasing concentration of hemoglobin produces an 
increasing effect (Figure 10a). However, the Ferrozine is able to bring the adhesion level to 
baseline when in the presence of hemoglobin.  
Figure 11 shows a biofilm assay prepared in glass tubes using several types of media. The 
results show that Ferrozine might be having an additive effect with the hemoglobin to increase 
adhesion of Candida to the plastic. This additive effect has also been shown for the 
transcriptional regulation of CaHMX1 (Pendrak et al., 2004).  Additionally, it is possible that by 
chelating the iron (II), the Filastatin has less of an effect.  
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Figure 10: Effects of the two Iron Chelators on the Interaction Assay: Varying Concentrations of 
Hemoglobin. Both (a) BPS (1 mM) and (b) Ferrozine (1 mM) were used in the SC media for this assay to 
mimic low iron conditions of the blood. The rest of the assay was performed as stated before. 
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Figure 11: Biofilm Formation of a Wild Type Strain in Different Media Types. Cultures were grown at 30˚C 
for 24 hours. Media types are listed above the biofilm growth, marked with an arrow. Hemoglobin was 
added exogenously at 10 µM concentration, Ferrozine at 1 mM, and Filastatin at 10 µM. Cultures were 
inoculated with 0.001 OD/mL of the wild type strain.  
 
 
Candida albicans can form biofilms on glass tubes when suspended in normal, SC media. 
Hemoglobin induces biofilm growth even in the presence of Filastatin, which is known to 
prevent adhesion (an early step of biofilm formation). This result can be quantified using the 
biofilm assay, when the strains are grown in 96-well plates for 20 to 25 hours. This result is 
shown in Figure 12.  
Based on Figures 11 and 12, the low-iron conditions coupled with available hemoglobin may 
induce biofilm formation, beginning by inducing adhesion (Figure 10b). The biofilm formation 
of the Ferrozine alone is not statistically different from the control media, indicating that the 
low-iron conditions without available hemoglobin or heme are not capable of inducing 
adhesion.  
Although not cogent to this thesis, it was readily observable that only those biofilms formed 
with Ferrozine and hemoglobin, together, turned red in color, a function of Ferrozine bound to 
Fe2+. Additionally, the cells, which would normally be free in solution, exhibited clumping. 
This could be due to the cells cohering within the media.  
Filistatin is not able to prevent adhesion, shown in Figure 11, when hemoglobin and Ferrozine 
are also present. This indicates that Filastatin may not be as effective in a low-iron environment, 
like the bloodstream.  
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Figure 12: Biofilm Formation of Wild Type Strain in Different Media Types. Ferrozine is at a 1 mM 
concentration, while Filastatin and hemoglobin are at 10 µM. The wells were inoculated with 0.01 OD/mL. 
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Discussion 
Filastatin was discovered in 2013 in an effort to find additional drugs to fight Candida albicans 
infections, especially those caused by adhesion to the plastics of medical devices (Fazly et al., 
2013). Before it can be used in the clinical setting, the target of the drug must be identified in 
order to better describe its mechanism of action. A reverse genetic approach was used and two 
screens were performed. Since there is no total knockout library for C. albicans, a mutant 
library enriched for transcription factors was used (Noble et al., 2010).   
The original screen (Figure 3) aimed to find mutants when in the presence of the drug would 
show an exaggerated response, i.e., significantly more or less adhesion. From this screen, 233 
mutants were isolated (Table 1). Of these mutants, several were involved in filamentation 
pathways, nutrient uptake, cellular responses, and many more pathways (based on GO analysis). 
Because this screen yielded such a large number of results, specific pathways were difficult to 
identify. A second screen, shown in Figure 4, was performed using the known function of 
Filastatin as a tool for the discovery of the target. This screen yielded only 43 genes (Table 2). 
The pathways isolated from this screen were adhesion and biofilm formation, which validated 
our screen, but, also, iron uptake. Because it was already known that Filastatin prevents 
adhesion, the iron-uptake pathway became the focus for the remainder of the project.  
The first step of the project was to confirm that the iron-uptake pathway is connected to 
adhesion processes. Therefore, the mutants of an iron-uptake pathway, rbt5, pga10, pga7, and 
hap43 were tested using the AFM, which measures the force that the cells exert on the surface 
(Figure 6). The results showed that mutants, rbt5 and pga10, which are missing extracellular 
structures responsible for acquiring hemoglobin/heme from the environment, are responsible for 
some adhesive force. It is known, in the field, that mutants lacking Rbt5, Pga10, or other similar 
proteins form weaker biofilms with less extracellular matrix (Kronstad et al., 2013). This result, 
in conjunction with the literature, indicates that the process of binding hemoglobin/heme may 
mediate adhesion. Additionally, according to Figure 7, Filastatin acts to reduce the adhesive 
force of the Candida on the glass surface. This suggests that Filastatin may be acting on the 
surface of the cell.   
Based on the results of the screen, it is possible that Filastatin is somehow interacting with 
the proteins of this iron-uptake pathway. More assays uncovering the relationship were 
performed using the CV stain in both an adhesion and biofilm assay. When hemoglobin was 
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added to the system, there was an increase in adhesion; the converse was true when Filastatin 
was added in increasing concentrations (Figure 9). If Filastatin is acting on the surface of the 
Candida, then both hemoglobin and Filastatin may be vying for the same receptor. Figure 8 and 
Appendix C show that there is an interaction between the two when both drugs are added to the 
system. If they were acting independently within their own mechanisms, then it would be 
expected that the effect of the two would be additive. That is, the adhesion promoting the effects 
of hemoglobin combined with the inhibitory effects of Filastatin would lead to an intermediary 
level of adhesion. In Figure 8a, when 15 µM of both hemoglobin and Filastatin are added, the 
adhesion is not restored to baseline. However, in Figure 8b, when 5 µM of each is added to the 
system, the result is baseline adhesion. This may indicate that there is an interaction or that 
hemoglobin is less effective at lower concentrations. Future experiments to test this interaction 
may include testing more concentrations of hemoglobin and Filastatin, based on Figure 9. 
Additionally, a test during which Candida is allowed to incubate with either hemoglobin or 
Filastatin followed by addition of the other may help elucidate whether or not these ligands are 
competing for the same receptor. This would help to answer two questions: 1) are they are 
acting within the same receptor, and if so, then when one is able to fill the receptors, can the 
other still be effective? and 2) Will this show the same level of effectiveness?  
The bloodstream is normally considered low-iron, thus two iron chelators, BPS and 
Ferrozine, were used to mimic this condition. BPS binds to Fe3+, which is found extracellularly, 
and normally found within Ferritin. Figure 10a shows that BPS does not seem to effect the 
results of the interaction assay. On the other hand, Ferrozine, which sequesters Fe2+ (Sheftel et 
al., 2012),  is able to increase adhesion to baseline when in the presence of hemoglobin. An 
additive effect between Ferrozine and hemoglobin has been seen in terms of the gene CaHMX1 
as well.  CaHMX1 is a heme oxygenase, which is necessary for C. albicans to survive when 
heme is the only available source of iron (Pendrak et al., 2004). Iron-uptake related genes have 
also been shown to affect filamentation (Xu et al., 2014), which is a precursor to biofilm 
formation.  
Biofilm formation was modeled in glass tubes incubated at 30˚C (Figure 11). Ferrozine 
media showed no difference compared to the control media. This indicates that although the 
iron is being chelated away from the media, adhesion is still occurring, at least at control levels. 
When hemoglobin is added to the system in a concentration of 10 µM, the adhesion (and 
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therefore biofilm formation) increases significantly (Figures 10b and 12). In vivo, the 
bloodstream is a low-iron environment, which can be modeled in vitro using Ferrozine in the 
adhesion assay and biofilm assay. The Filastatin was able to limit biofilm formation in the 
presence of hemoglobin, but in the low-iron conditions, biofilm was still able to form (Figure 
11). This is an indicator of how it may perform clinically, although this result will need to be 
quantified in the Biofilm Assay (plastic). However, the AFM studies (Figure 7) show that 
Filastatin is capable of limiting the adhesive force of Candida to glass surfaces. This may 
indicate that Filastatin’s purpose should be to coat the medical devices only, rather than acting 
within the bloodstream as a drug. Future studies should include testing the effectiveness of 
Filastatin to reduce the adhesive forces on plastics that medical devices are commonly made of. 
Additionally, in vivo testing, using murine catheter model (Andes et al., 2004) will be important 
to understand how Filastatin will act within a realistic model of infection both as a surface 
coating on the catheter and as an injectable drug.  
Other future studies might include biochemical or binding assays, which might require 
collaboration with a biochemist to prove that Filastatin requires Fe2+. Additionally, one could 
flood free iron to the system with Filastatin, either in the form of Ferritin, Fe3+, or a ferrous 
source of iron. This would show that when Filastatin is in the presence of Fe2+ (and not Fe3+), 
the cells are not able to adhere as well. In other words, available Fe2+ would enhance the effect 
of Filastatin.  
A significant amount of testing will need to occur before Filastatin can be implemented into a 
clinical setting. However, this study has shown that Filastatin may be acting within the iron-
uptake pathway, which is important for both virulence and adhesion. Additionally, Filastatin is 
not able to prevent biofilm formation in low-iron conditions, which mimic the bloodstream. A 
summary of these results can be found in Appendix D.  
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Chapter 3: Phenomics Panel on Several Clinical Isolates of Candida 
albicans  
Introduction 
Many systems can be used to study Candida albicans including: in vivo, ex vivo, and in vitro 
systems. An extensive phenomics report of clinical isolates is not often done. For this 
investigation, several phenotypes of two clinical isolate series, taken in a time course, were 
studied. The list of strains, including the clinical isolates and their sources, are shown in Table 
3.  
As a follow-up to the Filastatin experiments, the ability of the clinical isolates to adhere to 
plastic was tested. Candida albicans is able to adhere and form biofilms on both abiotic and 
biotic surfaces (Hogan et al., 2004; Mayer et al., 2013). Plastics, such as those used to 
manufacture medical devices, are common substrates for biofilm formation. Mature biofilms are 
more resistant to drugs and host responses (Li et al., 2012). The ability to adhere to abiotic 
surfaces would confer an advantage, thus more virulent strains would be better able to adhere to 
plastic.  
The clinical isolates were tested for virulence using C. elegans, a high-throughput model 
organism that has been used to monitor infection through several phenotypes (Ewbank, 2002; 
Garsin et al., 2003; Hodgkin, 2000; Pukkila-Worley et al., 2011). In this study, a visible 
phenotype, known as deformed anal region (Dar), was monitored. Dar is an inflammation of the 
post-anal region, which begins to appear by Day 3 (Jain et al., 2009). Additionally, the lifespan 
of C. elegans infected with each of the clinical isolates was tracked in a survival assay. It was 
hypothesized that any clinical isolate present during active infection would exhibit enhanced 
virulence. 
In addition to in vivo assays used to measure virulence, an ex vivo assay using the cultured 
murine macrophages, RAW264.7, was performed. Macrophages are one of the host’s first 
defense mechanisms, and they are able to engulf the fungi. The nutritional environment that the 
fungi face when engulfed is different and harsh (Filler and Sheppard, 2006; Lewis et al., 2012; 
Mayer et al., 2013), and thus, virulent Candida must be able to survive several conditions. The 
ability of the clinical isolates to survive when co-cultured with the macrophages can be 
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measured. More virulent strains are able to survive better and may even be capable of 
filamenting within the macrophages, causing them to burst (Lewis et al., 2013).  
Yeast cells are capable of performing a dimorphic transition between planktonic yeast cells 
and hyphal forms. Both forms are vital for pathogenicity (Mayer et al., 2013). It has been shown 
that the hyphal are more capable of invading both in vitro agar and epithelial cells in vivo. 
Finally, a host of in vitro phenotypes were tested. Morphology on starving media and the cell’s 
ability to invade agar were monitored. 
Because Candida are able to disseminate throughout the body to many organs, where the 
nutritional availability changes, several stressors were tested in vitro. These included metals, 
drugs, as well as varying temperatures. Metals, like iron, zinc, and copper, are known to be 
essential for growth of C. albicans, but the mechanisms by which the fungi acquire them are 
still poorly understood. In addition to metals, the growth in the presence of several drugs was 
monitored. Fluconazole is the most popular treatment for C. albicans; however, resistance is 
becoming a serious problem (Control, 2013). The final set of in vitro phenotypes was of varying 
temperatures, as heat shock proteins protect the yeast from death when the environmental 
temperatures change.  
Looking at the phenotypes present from each of the clinical isolate series, intraspecific 
comparisons can be made within each series. Additionally, the information regarding the host 
allows for interspecific comparisons.  
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Table 3: Sources of Strains including Clinical Isolates. Patient names (V and B) were assigned for ease of 
understanding. 
Sample Ploidy Source Patient 
SC5314 Diploid Wild type strain, 
laboratory derived 
reference strain 
N/A 
PN1 Tetraploid Vaginal swab sample 
Patient V* 
PN2 Diploid Commensal cheek swab 
FH1 Diploid 
Fecal samples 
Patient B**  
FH2 Diploid 
FH3 Diploid 
FH5 Diploid 
Blood samples FH6 Tetraploid 
FH8 Diploid 
RBY18 Tetraploid Laboratory  strain  
tetraploid 
N/A 
RBY16 Diploid Parent diploid of 
laboratory strain RBY18 
N/A 
MMY304 Diploid Parent diploid of 
laboratory strain RBY18 
N/A 
*Patient V had chronic vaginitis and was treated with antifungals. 
**Patient B received a bone marrow transplant and was also treated with antifungals. 
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Materials and Methods 
Growth Conditions for Yeast and Worms  
Yeast strains were maintained on YPD plates. Fresh plates were struck weekly from glycerol 
stocks, which were kept at −80˚C. The plates were stored at room temperature and wrapped in 
paraffin (Sherman, 1991). Before each assay, the strains were grown in liquid media overnight, 
spinning at 30˚C.  
The wild type strain of C. elegans, N2, were maintained at 20˚C on normal growth 
media (NGM) agar plates (Stiernagle, 2006). The plates were seeded with OP50 and the worms 
regularly transferred to fresh plates to avoid starving.  
Egg Preparation 
Worms were grown for four to five days on NGM agar with E. coli (OP50) at 20˚C. Eggs were 
washed off the plate with M9 buffer and centrifuged at 900 g for two minutes. The pellet was 
resuspended in a 1:4 dilution of commercial bleach (5.25%) containing 0.25 M sodium 
hydroxide solution, mixed gently by inversion, and centrifuged for two minutes at 2000 g. The 
pellet was washed with M9 and centrifuged at 2000 g. The egg suspension was diluted with M9 
and enough mix to obtain approximately 20 worms per plate were plated.  
Dar Assay 
E. coli and yeast strains were grown overnight at 37˚C and 30˚C, respectively. Culture aliquots 
were centrifuged at full speed for 10 minutes, washed with sterile water, and resuspended to a 
final concentration of 200 mg/mL and 10 mg/mL, respectively. A mixture of 10 µL of a 50 
mg/mL streptomycin sulfate stock, 7 µL of an amino acid solution (containing R-H-L-M-W, 
adenine, and uridine), 2.5 µL of the E. coli mix, and 0.5 µL of the yeast mix was prepared. 
Worms were prepared according to “Egg Preparation.” Plates were stored at 20˚C and observed 
beginning on day 3 until day 5, recording the number of worms displaying the phenotype (Jain 
et al., 2009). A z-test was used to check the statistical significance between the members of the 
PN series and among the members of the FH series.  
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Survival Assay 
For survival analysis, test plates and C. elegans eggs were prepared according to the “Egg 
Preparation” and “Dar Assay” methods. Each plate was seeded with 20–25 eggs. Beginning on 
the third day after plating the eggs, the number of dead and live worms was recorded on each 
plate each day. Live worms were transferred to a new plate as necessary to avoid confusing the 
worms with their progeny. Subsequent plates were of the same composition as the original test 
plates. Graphpad prism was used to create and analyze the Kaplan Meier survival curves. 
Significance, as defined by a p-value less than 0.05 was assessed using the Gehan-Breslow test. 
Worms that left the plate were “censored,” i.e., removed from the counts on subsequent days. 
The Gehan-Breslow test assumes that the data from early survival times are more accurate than 
data from later times and weights them accordingly.  
Macrophage Assay 
RAW 264.7 (ATCC) was used for this assay. The cell line was maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) supplemented with 10 percent fetal bovine serum (FBS) and 
one percent penicillin/streptomycin. Macrophages, upon reaching 80–90 percent confluence, 
were scraped and brought up in supplemented DMEM. 2 × 106 cells were plated in three wells 
of a six-well plate and allowed to adhere for five hours. Candida strains were grown in YPD 
media overnight at 30˚C and diluted 1:10 with fresh media, then allowed to grow for another 
five hours. Candida cells were counted, suspended in DMEM, and added to the plate containing 
macrophages in a ratio of 1:15 macrophage to a final volume of 2 mL. The yeast strains were 
grown in parallel in the other three wells of the six-well plate without macrophages to calculate 
percent survival. Plates were incubated overnight at 37˚C and five percent CO2. Cells were 
brought up to 24 mL in a 50 mL conical tube using 0.05% Triton X-100 (v/v) in water to 
osmotically lyse the macrophage cells. Conical tubes were vortexed for one minute and serial 
dilutions were carried out immediately after. Two dilutions were plated on YPD plates and 
grown overnight at 30˚C. Colony forming units (CFU) were counted and percent survival was 
calculated by taking the ratio of CFU from the co-culture of Candida and macrophage to the 
CFU obtained for Candida alone.  
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In vitro Phenotypic Profiling Assays 
Plates were prepared using synthetic complete (SC) media (Sherman, 1991) supplemented with 
0.15% glucose, amino acids (R-H-L-M-W), adenine, and uridine. Drugs and stressors were 
added as necessary to the liquid media before pouring.  
All of the clinical isolate strains were obtained from Dr. Judith Berman at the Tel Aviv 
University, Israel. Reference strain for the tetraploid and its diploid parents were obtained from 
Richard Bennett at Brown University. Two to three days before beginning each assay, strains 
were struck from frozen stock onto YPD plates and grown at 30˚C overnight. These plates were 
stored at room temperature for one week. The night before the assay, a liquid culture in YPD 
media was started and incubated at 30˚C. Strains were centrifuged and resuspended in water to 
1 OD/mL and serial dilutions were made using dH2O as well. Using a multichannel pipet, 5 µL 
of each dilution was added to the plates for each strain. A wild type reference strain was 
included with each set of clinical isolates. Plates were stored at 30˚C unless otherwise stated. 
Plates were photographed with an iPhone camera one, three, and five days post spotting. The 
pictures were analyzed using ImageJ software. Heat maps were created for each condition using 
Excel.  
Adhesion Assay 
Single colonies were picked and inoculated into 5 mL cultures of SC + 0.15 percent glucose 
media and grown overnight in a rotating wheel. The optical density (OD) of the cultures was 
then measured at OD600 nm. Cultures were spun down and resuspended in fresh SC + 0.15 
percent glucose to a final concentration of 0.5 OD/mL.  200 µL of 0.5 OD/mL C. albicans 
strains were pipetted onto 96-well flat-bottom polystyrene plates. Plates were covered with 
aluminum foil and incubated at 37˚C for four hours. After four hours of incubation, plates were 
decanted, and 40 µL of 0.5 percent crystal violet (CV) stain was added to each well. The plates 
were covered and left at room temperature to incubate for 45 minutes. Plates were then decanted 
and washed by submersion 10 times in an ice bucket filled with dH20, changing the water every 
five washes. Plates were tapped onto a paper towel to remove residual dH20, and 200 µL of 75 
percent MeOH was added to each plate and incubated at room temperature for 30 minutes. The 
plates were then read at 590 nM to detect relative absorbance.  
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Results 
Several phenotyping assays were performed in this study comprising in vivo, ex vivo, and in 
vitro tests of the clinical isolates. For each assay, the clinical isolates listed in Table 3, were run 
in parallel to the reference lab strain, SC5314. This strain began as a clinical isolate, but has 
been maintained in many laboratories since the late 1960s (McRipley et al., 1979), and thus has 
most likely lost the characteristics of clinical isolates. However, because it is commonly used as 
the wild type strain in most experiments involving C. albicans, for this study it will be a 
reference strain. Additionally, SC5314 acted as an experimental control for the in vivo and ex 
vivo assays to make sure that they were working properly as this strain has been tested 
previously. The resulting information of these assays for both sets of clinical isolates were then 
analyzed to make important connections about their virulence.  
In vitro: Adhesion Assay 
Initially, the clinical isolates were tested for the ability to adhere to plastics (Figure 13). It is 
possible that cells with increased capacity for adhesion would be more likely to invade the 
bloodstream (Bliss et al., 2012). Additionally, adhesion is the first step in biofilm formation, 
which can be modeled by this assay (Figure 2). This is important because C. albicans is capable 
of forming biofilms on plastic medical devices. According to Figure 13, PN1 shows 
significantly more adhesion than PN2 based on an unpaired t-test (p < 0.0001). Of the FH 
Series, FH3 shows significantly more adhesion, which indicates that it is more virulent than the 
other strains in this series, analyzed by a one way ANOVA, with Tukey’s multiple comparison 
test.  
In vivo: Dar Assay 
C. elegans is a useful model for studying virulence of fungal pathogens, such as C. albicans. 
The  deformed anal region (Dar) phenotype (Jain, 2013) presents three days post-infection, and 
can be seen until death. However, useful comparisons stop after day five when the plates 
become overcrowded with progeny and the worms begin to die off. Beginning on day four, 
SC5314, the reference strain, shows close to 100 percent Dar. Any amount less than this on day 
four would indicate a less virulent strain. In addition, 100 percent Dar on day three would 
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indicate increased virulence compared to the reference strain. Figure 14 shows the results of 
testing the clinical isolates for Dar on day four and five.  
 
 
Figure 13: Adhesion, Measured by Absorbance at 590 nm, of Each of the Clinical Isolate Strains. Error bars 
are a measure of SEM. 
In Figure 14a PN2, the commensal strain, shows significantly less (p < 0.05)  Dar phenotype 
as compared to its counterpart PN1, which was isolated during an active infection episode. This 
indicates that PN2 is less virulent. The phenomenon persists through day five (Figure 14b) 
when PN1 becomes 100 percent.  
The FH series was also tested in the Dar assay. These strains have similar virulence as shown 
in Figure 14a, day four. FH2 is the only strain below 90 percent, making it significantly 
different from FH5 and FH6 (p < 0.05). However, on day five, all strains reach 100 percent. 
FH2 may be less virulent than some of the other strains, although the results are far less clear 
than those of the PN series. It was necessary to perform the second in vivo assay modeling 
lifespan in the presence of the drug.   
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Figure 14: a) Day 4 Dar Measurements of the Reference Strain, SC5314, the PN Series, and the FH Series. b) 
Day 5 Dar measurements of the reference strain, SC5314, the PN Series, and the FH Series. Error bars 
represent standard error of proportion in these figures. 
In vivo: Survival Assay 
In addition to the Dar assay, virulence can be measured using the survival assay, which models 
the nematode’s lifespan by substituting their normal food with yeast. Uninfected, wild type C. 
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elegans, N2, live for 21 days at 20˚C. The clinical isolates survived for only 14–16 days, with 
the exception of PN2, which maintained 50 percent survival by day 16. Two types of statistical 
analysis were used: the log rank test and the Gehan-Breslow test. The log rank test is most 
commonly used in the field and assumes that the ratio of hazards is the same at each time point, 
while the Gehan-Breslow test places a greater value on the deaths in the early days.  Only the p-
values of the Gehan-Breslow test are reported within the text, but Table 1 in Appendix E shows 
a compilation of the p-values from both tests.  
 
 
 
Figure 15: Survival Comparison between PN1 and PN2 
According to Figure 15, by day 11, 50 percent of the worms exposed to PN1 had died, which 
can be compared to worms infected with PN2, where 50 percent of the infected worms had 
survived until day 16. These results indicate that PN2 is significantly less virulent (p = 0.0049) 
than its counterpart, mimicking the results from the Dar assay. Median survival times, shown in 
Table 4, are also a useful tool for indicating virulence. For instance, the median survival time 
for PN1 is 12.0 days, while the median survival time is undefined for PN2. The worms living in 
the presence of PN2 tended to live longer and thus had more time to crawl off the plate. By day 
16, there were no longer any worms to score on the plate.   
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Table 4: Median Survival Time for Clinical Isolate Strains in Survival Analysis 
 
 
Figure 16: Survival Analysis of the FH Series 
The FH series was also tested in survival, and visually, the results, shown in Figure 16, 
appear closely matched for each strain. According to the Gehan-Breslow test, the curves are 
significantly different (p < 0.0001). FH3 shows the most death early on, killing 25 percent by 
day four. FH5 takes eight days to reach this same percentage of death. However, the median 
survival times are not different. As shown in Table 4, the median survival is nine days for FH1, 
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FH2, FH6, and FH8, while FH3 and FH5 have a median survival time of 10 days. Based on the 
data from the Dar and survival assays, there is little difference in the virulence of the FH series.  
Ex vivo: Macrophage Assay 
To further characterize the pathogenicity of the clinical isolate series, an ex vivo assay was used 
to measure survival of C. albicans when exposed to cultured murine macrophages, RAW 264.7. 
This ex vivo test is an effort to mimic the biology of the host–pathogen interaction. It is known 
that the macrophages engulf the yeast cells and either kill or render them incapable of 
multiplying (Lewis et al., 2012). A strain that shows a high ratio of colony forming units (CFU) 
of co-culture with macrophage to CFU of Candida alone is more virulent as the macrophages 
have less of an effect on that strain. However, if the macrophages are capable of killing a high 
number of the yeast cells, then the ratio would be lower, and the strain less virulent.    
Figure 17a shows that PN1, at 63 percent survival in the presence of the macrophage, is 
significantly more virulent than PN2, the commensal strain, which showed only six percent 
survival. Similarly to the survival assays, the clinical isolates in the FH series all show relatively 
similar survival in the presence of the macrophage, less than 10 percent (Figure 17b). However, 
of this group, FH3 is shown to be the most virulent, which can be correlated to the early days of 
the survival assay. Interestingly here, FH1 is less virulent, but in both the Dar and Survival 
assays, FH1 showed similar virulence levels to the other strains in the series.  
Based on the data from the in vivo and ex vivo assays, PN1 is clearly more virulent compared 
to PN2. This is likely because it was isolated from an active infection. The FH series all show 
similar levels of virulence in each of the previous assays. The in vitro tests can be used to 
elucidate some differences among the strains, which could provide useful information for 
treatment.  
In vitro: Morphology 
There are several ways to examine the morphology of yeast. The first is by plating the yeast on 
spider media (Lo et al., 1997) to induce filamentation, shown in Figures 18 and 20. The second 
is through an invasion assay, which can potentially model invasion of the Candida into the 
bloodstream through the blood vessels or the epithelial layers of the gut (Dieterich et al., 2002).  
To test invasion, cells were spotted on agar plates and incubated at 30˚C.  Then the cells were 
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scrubbed off the surface under a gentle stream of water.  Attached cells were photographed 
(Figures 19 and 21). 
 
 
 
Figure 17: Results of the Ex Vivo Macrophage Assay for a) the PN series and b) the FH series. Percent 
survival is found by taking the ratio of co-cultured yeast with macrophages to yeast alone. Error bars 
represent SEM. 
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Figure 18: Attached Cells. Filamentation forms under starved conditions on spider media of PN strains 
grown at 30˚C for 10 days. 
 
 
Figure 19: Invasion of PN1 and PN2. Samples were grown on YPD Plates for 10 days at 30˚C and run under 
distilled water to clean off the spot, revealing the invasion into the soft agar. 
According to Figure 18 and 19, PN2 is more filamentous and invasive than PN1. This may 
seem counterintuitive to results presented earlier using the C. elegans model and the ex vivo 
macrophage model of infection. PN1, which was isolated during an infection, was more virulent 
than PN2, the commensal strain. Filamentous cells are important for attachment, however 
normal yeast cells are important for dissemination of the infection (Ariyachet et al., 2013; Filler 
and Sheppard, 2006). It is thought that mucosal infections, like thrush or vaginitis, are more 
commonly associated with the yeast cell form, whereas internal organ infections require the 
filamentous form.  
In the FH series, FH2, FH3, and FH6 showed limited ability to filament compared with FH1, 
FH5, and FH8. It is interesting to note that FH1, FH2, and FH3 were isolated from fecal 
samples, while FH5, FH6, and FH8 came from blood samples. This may correlate with the 
PN1 PN2 
PN1 PN2 
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results from the PN series, as the strains that are more likely infections of the lining of the 
intestine—FH1, FH2, and FH3—will likely present in yeast budding form (Figure 20). These 
strains also showed less invasion of the soft agar (Figure 21) than the strains that were isolated 
from the patient’s blood—FH5, FH6, and FH8.  
 
 
Figure 20: Attached Cells. Filamentation forms on spider media of the FH series and reference strains. The 
samples were grown at 30˚C for 10 days. 
In vitro: Stress Conditions 
Phenotypic profiling, using in vitro plate modeling, has been performed on several Candida 
albicans mutants in order identify the function of many transcriptional regulators (Homann, 
2009). In this work, a similar, phenotypic profiling was performed in order to elucidate the 
differences among strains acting within a single patient. It is possible that this work could be 
used as a model for profiling other clinical isolates to better inform treatment plans. 
Additionally, the heat maps produced show that the strains from a single patient do not reflect a 
uniform phenotype, indicating that each new infection must be treated differently.  
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Figure 21: Filamentation Induced by Invasion Assay on YPD Soft Agar Plates of the FH Series. Samples 
grown at 30˚C for 10 days. 
Figure 22 shows a heat map produced by comparing the colonies formed (SC5314, PN1, and 
PN2) on the plate under stress conditions such as acid/base, metal, drug, or temperature. The 
darker grey or black, indicates that a strain was more resistant (or able to grow unabated) to the 
condition while the white indicates that the strain was susceptible (or exhibited less growth) 
under that condition. It is interesting to note that there are several conditions where PN2 is more 
resistant to a particular condition. Having been isolated from the mouth, and exposed to several 
changes in environment, it is expected that this commensal strain would be more resistant to 
such conditions as acid, base, and cooler temperatures. PN1, unfortunately for the patient, is 
more resistant to the drugs Fluconazole, Fluphenazine, and Rapamycin.   
The same type of heat map was created for the FH series. Figure 23 shows that FH2 is often 
more resistant to the in vitro stressors. From this heat map, it can be inferred that the individual 
infections of this patient respond differently to the stressors, which may be an indicator that 
methods of prescreening are needed prior to administering drugs. For instance, shown in Figure 
23, the patient’s infection when FH6 developed may have been more responsive to Rapamycin 
than any of the other drugs. Additionally, the other strains may not have responded as well to 
FH1 FH2 FH3 
FH5 FH6 FH8 
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this treatment. If the infections cannot be phenotypically profiled in some manner, based on 
these heat maps, a cocktails of drugs, rather than a single drug would be a more effective 
treatment providing that the patient can tolerate it.  
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 Figure 22: Heat Map Indicating Relative Responses to Each Stressor. Black Indicates more resistance and 
white more sensitivity. The reference strain, SC5314, was plated as well for comparison purposes. 
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Figure 23: Heat Map Showing the Response of the FH Series to Each Stressor. Black indicates more 
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Discussion 
A series of phenotyping assays was performed on two clinical isolate series. The series were 
collected in a time course from two patients with active infections. Patient V (Table 3), a name 
randomly assigned for anonymity of the patient, was otherwise healthy but was plagued with 
chronic vaginitis, which affects up to 75 percent of women at some point during their lifetimes 
(Hong et al., 2014). PN1 was isolated from the active infection, and PN2 was taken from a 
cheek swab while no infection was present, also known as a commensal strain. This patient was 
treated with Fluconazole, the first line of antifungal treatments. On the other hand, the FH series 
was isolated from a patient (Patient B, Table 3) who was immunocompromised from a bone 
marrow transplant. This patient contracted an invasive Candida infection from the transplant 
and was treated with Fluconazole as well (FH1 and FH2 were collected before treatment began) 
(Abbey et al., 2014). The information from the host could prove useful in making interspecific 
connections between series.  
The results of the phenotyping assays in this study show, of the PN series, that PN1 is the 
most virulent. This can be seen in the in vivo assays, both Dar and survival (Figures 14 and 15), 
the ex vivo assay (Figure 17), and the in vitro adhesion assay (Figure 13). Interestingly, PN1 
shows little filamentation (Figure 18) and no invasion into agar (Figure 19), which means that 
when it was isolated from the patient it was in the yeast cell form. Virulence has been linked to 
the ability of C. albicans to switch between cellular and hyphal forms, and those that switch are 
more virulent. From this study alone, it cannot be proven that in vivo, PN1 is not switching to 
the hyphal form. It is interesting to correlate the yeast cell form with the mucosal infection 
though, as the cells do not need to invade the organs. The commensal strain, PN2, showed 
filamentation (Figure 18) and invasion (Figure 19), which could indicate that the commensal 
strains are actively working to invade the bloodstream and become active infection. This cannot 
be proven from this study alone, but more work analyzing differences between infectious and 
commensal strains is necessary. Additionally, it may be possible that PN1 has suffered a fitness 
cost for being Fluconazole resistant. That is, PN1 has given up the ability to filament in order to 
possess this advantage of Fluconazole resistance (Selmecki et al., 2010).  
The FH is not as clear-cut as the PN series in terms of which strain is the most virulent. This 
could be because the patient from whom the strains were isolated was immunocompromised, 
and therefore the strains were not required to be as virulent. The in vivo tests, Dar (Figure 14) 
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and survival (Figure 16), showed little difference between the majority of the strains. While it 
appears that there is a difference between FH3 and all other strains (except FH6) in the ex vivo, 
macrophage assay. According to the filamentation assay (Figure 20), the strains that were 
isolated from fecal samples, which would indicate infection of the gut, showed less 
filamentation than those isolated from blood samples, indicating invasive infections. This result 
is also connected to Figure 21, the invasion of the soft agar. It can be seen from these assays 
that within a single patient, there is no uniform phenotype for Candida infections, thus it is 
unlikely that each new infection would respond to the same drug.  
The in vitro plate assays of stress conditions could provide insight into possibilities of 
screening for treatment for each individual infection. Because there was no clear pattern among 
this clinical isolate series, it is clear that each infection should be treated as a unique infection. 
New technologies utilizing 96-well formats (Shea et al., 2012) for phenotyping assays could 
prove useful for quickly and accurately deciding which treatment to administer. For the FH 
series, FH2, showed resistance to acidic conditions, thus a more basic drug might be considered 
first, while FH3 and FH5 are more susceptible to acid, and thus may respond to acidic drugs 
better (Figure 23). FH2 and FH8 are resistant to the drug Fluphenazine, which indicates it 
would not have been a good treatment; FH1, however, is more susceptible, and thus may have 
been a good choice for the initial treatment (Figure 23). Additionally, FH6 is susceptible to 
Rapamycin, the original antifungal antibiotic, but it is now used in transplants for its 
immunosuppressive effects (Sehgal et al., 1975). An interesting and novel result is that FH3 is 
susceptible to Filastatin, a new drug affecting filamentation and adhesion (Figure 23) (Fazly et 
al., 2013). FH3 showed increased adhesion to plastics in the first, in vitro assay of this 
phenomics study (Figure 13), indicating that Filastatin may be a useful treatment at the bedside. 
Because there has been a significant increase in Fluconazole resistant C. albicans infections, 
more drugs are needed to fight infection (Control, 2013). In addition to potentially using a new 
method of prescreening, described above, or cocktails of drugs, rather than the go-to drug, 
Fluconazole, new drugs, like Filastatin, will need to be discovered or developed.  
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Abstract: Pathogenic fungi cause superficial infections but pose a significant public health risk 
when infections spread to deeper tissues, such as the lung. Within the last three decades, fungi 
have been identified as the leading cause of nosocomial infections making them the focus of 
research. This review outlines the model systems such as the mouse, zebrafish larvae, flies, and 
nematodes, as well as ex vivo and in vitro systems available to study common fungal pathogens. 
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1. Introduction 
 
Fungi are ubiquitous and can grow in the mucous membranes and intestinal tracts and on the 
skin. They are also found in the soil and on plants, trees, and other vegetation. Although not all 
fungi are pathogenic, some can cause serious disease and pose a significant public health risk. 
Within the last three decades, fungi have been identified as the leading cause of nosocomial 
infections (Pfaller, 2007; Prevention, 2014c) especially among immunocompromised patients. 
This review first outlines the host systems available to study some of the common fungal 
pathogens, of the genera Candida, Cryptococcus, Histoplasma, and Aspergillus (Pfaller, 2007) 
(Figure 1). 
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Figure 1:  Relative relatedness of the genera discussed in this paper. S. cerevisiae and S. pombe are used as 
references for comparison. The arm lengths on the phylogenetic tree are representative and not actual 
evolutionary distances. 
 
1.1 Candida 
Yeasts that belong to the genus Candida can cause both superficial and invasive infections. 
Superficial infections include oropharyngeal infection or “thrush,” vaginitis (commonly called 
“yeast infection”), and diaper rash. While superficial infections are often persistent, they are 
usually not life threatening. However, when Candida invades the bloodstream, the infection 
becomes systemic and is often deadly (Control, 2013; Prevention, 2014b). Fungi in the Candida 
genus have emerged as major human pathogens, becoming the fourth leading cause of 
bloodstream infection (BSI) in hospitals around the United States, with 7,000–28,000 annual 
reports of BSI with a Candida (Pfaller, 2007). Some strains, specifically C. albicans, are 
becoming increasingly resistant to conventional antifungal treatments (Pfaller, 2007). For 
example, in 2013 the United States Center for Disease Control (CDC) reported that fluconazole 
resistant Candida albicans poses a serious threat and is responsible for approximately 3,400 
cases annually, including those that are superficial as well as those in the bloodstream (Control, 
2013). The lifestyle and virulence strategies used by C. albicans are the subject of intense 
research (Pfaller, 2007). A BSI often begins with a biofilm on medical devices, such as dental 
implants, catheters, heart valves, bypass grafts, ocular lenses, artificial joints, and central 
nervous system (CNS) shunts (Prevention, 2014c). In persons whose gastrointestinal tract is 
heavily colonized by C. albicans, it is thought to invade the epithelium in the villi and cross into 
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the bloodstream. The most common non-albicans infections seen are caused by the emerging 
opportunistic pathogens C. parapsilosis, C. tropicalis, and C. glabrata. 
Candida parapsilosis is also capable of forming biofilms on catheters, which can lead to 
systemic infection if the catheter is placed before removing the yeast (Prevention, 2014c). 
Candida glabrata, evolutionarily a distant relative of C. albicans, was once considered 
nonpathogenic (Prevention, 2014c). With the increasing incidence of AIDS and corresponding 
rise in the use of immunosuppressive agents, C. glabrata infections have also increased. C. 
glabrata is the second or third most common causative agent of superficial and systemic 
Candida infections. It is often difficult to treat because it is resistant to many azole antifungal 
agents (Fidel, 1999). Candida tropicalis is the fourth most common species of the Candida 
genus (Pfaller, 2007). It is common among patients with hematologic malignancies. It is 
sensitive to azole drugs and other antifungal agents, which have decreased the incidence of C. 
tropicalis within the United States. However, worldwide, its incidence continues to rise, which 
makes it a candidate for study (Pfaller, 2007). 
 
1.2 Cryptococcus 
There are approximately thirty species of Cryptococcus, the most prevalent pathogen being 
C. neoformans. Cryptococcus neoformans can be found in soil throughout the world. Humans 
become infected by inhaling microscopic spores, which can cause mild symptoms to serious 
lung infections (Prevention, 2014a). C. neoformans is also responsible for cryptococcal 
meningoencephalitis, which occurs in immunocompromised individuals. It can be found 
worldwide and is commonly fatal in sub-Saharan Africa (Price, 2011). Cryptococcus gattii, a 
lesser known species of Cryptococcus, can infect immunocompetent hosts and is found most 
prominently in tropical and subtropical areas. However, in 1999, there was an outbreak of C. 
gattii on Vancouver Island, Canada. This geographic expansion in its range has resulted in 
intense epidemiological studies (Fraser, 2005). 
1.3 Histoplasma 
Histoplasmosis, caused by the fungus Histoplasma capsulatum, is a rare infection but is  
important to study because of its wide host range, typically mammals. Histoplasma capsulatum 
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is thought to enter a latent stage that can be reactivated to active histoplasmosis when the patient 
has a weakened immune system (Rappleye, 2004) even several years post-exposure. Found in 
the environments most commonly associated with bird and bat droppings where nitrate content 
is high, H. capsulatum lung infections on inhalation of airborne spores, which produces 
pneumonia-like symptoms (Prevention, 2014d). 
1.4 Aspergillus 
The genus Aspergillus is a fungi common in the environment because the spores are 
aerosolized. Unlike healthy individuals, who are able to expel the spores from their airways, 
immunocompromised individuals are unable to, which can lead to serious infection, initially in 
the lungs and then spreading to almost any organ. The two species that are most commonly 
associated with disease are A. fumigatus and A. flavus (Willger, 2008). During infection, A. 
fumigatus causes significant inflammation and necrosis of the lung tissue through hyphal 
growth, restricting oxygen availability in the tissue (Hedayati, 2007). A. flavus is the second 
leading cause of invasive aspergillosis and the most common for superficial infections. For 
reasons that are unclear, in certain hospitals it is more common in the air than A. fumigatus 
(Rappleye, 2004). 
2. Animal Models 
Several animal hosts have been used to study fungi that cause these common infections 
(Figure 2). Each model has its limitations, but can also yield useful information. Therefore, it is 
crucial that researchers choose an appropriate model best suited to address the experimental 
hypothesis being tested. The most common host systems are mice, zebrafish larvae, fruit flies, 
and nematodes. 
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Figure 2: Summary of various model hosts used to study fungal pathogens 
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2.1 Mus Musculus 
The murine model for infection is well developed because of its direct implication for human 
systems. The mouse has been used to model oral, vaginal, and systemic infections that have 
been shown to mimic human infection (Conti, 2009; Fidel, 1996; Takakura, 2003). 
Approximately 90 percent of HIV and AIDS patients experience an episode of 
oropharyngeal candidiasis or “thrush.” Rabbits and rats have also been used to model oral 
infections, but these animal models did not accurately mimic local symptoms of oral infection 
in humans (Takakura, 2003). A murine model showed typical lesions, associated with disease, 
allowing for more accurate quantification of the disease burden (Conti, 2009). This model for 
oral Candida infection has significantly contributed to our understanding of the disease (Jr, 
2002; Koh et al., 2008; Kumamoto and Vinces, 2005a). For example, it has been used to show 
that Th17 helper T-cells and their secreted cytokine IL-17 have a protective role against oral 
candidiasis. Oral candidiasis can lead directly to deep tissue (esophageal or stomach) or 
systemic Candida infections (Thewes, 2007). 
Recurring vulvovaginitis, which affects approximately five to ten percent of healthy women 
of childbearing age, is primarily caused by C. albicans or C. glabrata. A murine model to 
understand the effects of vaginitis has been developed (Wormley, 2001). Women with diabetes 
are particularly at risk for developing vaginitis. This is an important correlation between 
vulvovaginitis and Candida strains, which was used to validate this model. A diabetic mouse 
model was more susceptible to C. glabrata vaginal infections. Greater than 85 percent of mice 
showed organisms in lavage fluid and a 25 percent mortality rate by day 10 (Fidel, 1999). 
Introducing fungi directly into the tail vein of mice, mimicking a BSI, is widely used (Ikeda, 
2000; Lopez-Berestein et al., 1984) and is considered “the Gold Standard” in the field. This 
model is used to verify genetic determinants of virulence that have been identified using 
alternate methods. It is also useful for testing the efficacy of antifungal therapies. Because of 
resistance, new antifungals are in high demand. In order to model antifungal resistance in 
mammals, venous tail injection of Candida strains including albicans and tropicalis as well as 
Aspergillus fumigatus have been used. The murine model allows for multiple controlled doses 
of the antifungals (Ikeda, 2000). 
While the mouse is the smallest mammal that mimics many fungal diseases of humans, the 
model has serious limitations. These include: ethical considerations that prohibit testing on large 
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numbers of animals; the small sample size (n) makes it challenging to observe small 
differences; the fungal burden introduced in the bloodstream via the tail vein can overwhelm the 
immune system of the mouse, while lower fungal burdens escape detection or do not yield 
statistically reproducible results; the mouse is also not experimentally tractable for hypothesis-
driven research; lastly, knockouts are expensive, time consuming, and laborious. Therefore, to 
test mechanistic hypotheses involving multiple genes, other experimentally tractable facile models 
such as zebrafish, fruit flies, and nematodes, are used. 
2.2 Zebrafish 
Zebrafish have been used extensively to study developmental biology (van der Sar et al., 
2004). Recently, they have been used as vertebrate model hosts to study the interface between a 
fungal pathogen and the host immune system. Zebrafish express cytokines, macrophages, 
neutrophils, dendritic cells, mast cells, eosinophil, T-cells, and B-cells that are evolutionarily 
related to those of humans (Tobin, 2012). Phagocytes are the primary line of defense against 
fungal infections. In defense, C. albicans has been shown to hyphae that can escape the 
phagosomes (Liu et al., 1994; Lo, 1997; Lorenz et al., 2004). 
Phagocytes, neutrophils, and macrophages, ingest the fungi and inactivate, via multiple 
mechanisms, including reactive oxygen species (Jain, 2013; Jain et al., 2009) and reactive 
nitrogen species (Németh). Patients with neutropenia or defects in NADPH oxidase present an 
increase in infections with C. albicans (Lopez-Berestein et al., 1984; Robbins et al., 2010). 
Zebrafish larvae are transparent, and therefore, dissemination of the infection can be 
microscopically tracked (Brothers, 2011) offering a unique perspective compared to adult fish. 
Furthermore, larval innate immunity can be efficiently modulated using antisense morpholino 
mediated gene knockdown (Summerton and WELLER, 1997). 
The dimorphic transition between hyphal and yeast from cells is an important virulence 
determinant for C. albicans. The tup1 mutant of C. albicans is locked in a filamentous form and 
is avirulent in a murine model (Braun and Johnson, 1997). As a corollary, the cph1efg1 null 
mutant of C. albicans is restricted to yeast form cells under most conditions (Kumamoto and 
Vinces, 2005b; Rao et al., 2010), due to mutations in the master regulator of hyphal growth. 
This mutant has been shown to be less virulent in mice, fruit flies, and nematodes (Brennan, 
2002; Chamilos, 2006; Pukkila-Worley et al., 2011). Zebrafish were exposed to the cph1efg1 
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mutant as a test of virulence. Using fluorescent imaging in the transparent larvae, the non-
hyphal forming mutant strain was shown to be less virulent in zebrafish larvae (Brennan, 2002). 
Imaging the macrophages and neutrophils infected with C. albicans gave an in vivo view of 
phagocytosed C. albicans surviving and/or dividing. This in vivo evidence leads to the 
conclusion that production of reactive oxygen species by the phagocyte’s NADPH oxidase, 
which has previously been implicated in mice and nematodes (Chávez et al., 2007; Frohner et 
al., 2009), also provides resistance to C. albicans in zebrafish (Brothers, 2011). 
While zebrafish are a smaller vertebrate alternative to the murine model, it has certain 
limitations. Like the mouse, propagation of the fish requires a substantial capital investment for 
a facility and the personnel to maintain them. Furthermore, zebrafish are typically infected via 
microscopic injection that requires handling of individual animals, and is thus labor intensive. 
2.3 Drosophila Melanogaster 
Drosophila melanogaster is a well-developed experimental system used to model many 
aspects of biology (Kornberg and Krasnow, 2000). It has a short life cycle and is easy to 
maintain and manipulate with a large collection of mutant lines. Used as a host for gram-
positive and negative bacteria (Leclerc and Reichhart, 2004) and more recently, fungi (Alarco et 
al., 2004), D. melanogaster immunity has been shown to possess extensive conservation with 
mammalian innate immunity pathways, which make it a strong model system. Drosophila 
hemocytes mimic phagocytes in vertebrates, but they lack an acquired immune system. The D. 
melanogaster innate immune response is characterized by the production and release of stable 
antimicrobial peptides by the fat body. 
Direct injection of the fungal pathogen into the hemolymph results in a systemic infection 
and allows for precise calculation of fungal burden. Wild type flies are able to contain a 
systemic infection but unable to kill injected yeast. Flies with a mutation in the toll pathway 
succumb to systemic fungal infections. This immunodeficient fly model has been used as a host 
for the study of infectious agents (Glittenberg, 2011; Leclerc and Reichhart, 2004; Lemaitre et 
al., 1996; Quintin et al., 2013). 
The infectious agent can also be introduced into the normal Drosophila diet, although there 
is no way to accurately monitor intake (Chamilos, 2006). The feeding protocol is amenable to 
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scale-up studies for unbiased mutant screening to uncover novel virulence mechanisms. In 
addition, antifungal agents can be mixed in with their normal diet for studies of drug efficacy. 
2.4 Caenorhabditis Elegans 
Like D. melanogaster, the nematode, Caenorhabditis elegans, has been used extensively as a 
model system to study various biological phenomena, due to many positive aspects including a 
rapid lifecycle, its completely sequenced genome, genetically identical progeny (due to self-
fertilization), and a transparent cuticle that facilitates whole animal microscopy (Stiernagle, 
2006). More recently, it has been used as an animal model for the study of infectious disease 
(Ewbank, 2002; Garsin et al., 2003; Hodgkin, 2000; Jain, 2013). Nematodes are exposed to the 
infectious agent in their diet, therefore multiplicity of infection is not easily determined 
(Mylonakis, 2002). Fungi concentrate distally to the pharyngeal grinder and infected worms 
show a distended gastrointestinal system (Jain, 2013; Jain et al., 2009; Mylonakis, 2002). 
Caenorhabditis elegans has been a host model for many gram-positive and gram-negative 
bacterial infections such as Salmonella typhimurium, Pseudomonas aeruginosa, and 
Staphylococcus aureus.  Certain long-lived C. elegans mutants show immunity to these 
bacterial infections (Mahajan-Miklos, 1999). Recently, C. elegans was used as a host to study 
fungal diseases, but more importantly discoveries made in worms recapitulate virulence patterns 
in mouse and human infection (Mylonakis, 2002). For example, several virulence genes, 
including protein kinase A (PKA), protein kinase R (PKR), and G-protein alpha (GPA) were 
first identified in C. neoformans, which modulates virulence in C. elegans (Mylonakis et al., 
2004). These same genes were later shown to be important for Cryptococcus infection in 
mammals (Mylonakis, 2002). Disrupting PKA increases virulence of C. neoformans in mice 
(D'Souza et al., 2001), a phenomenon that was replicated in C. elegans.  
Infected nematodes show a deformity in the post-anal region (Dieterich et al.), which is 
visible four- to five-days post-infection (Hodgkin, 2000; Jain, 2013). Other disease markers 
such as swelling in the vulvar region and intestinal distention have been reported for both fungal 
and bacterial infections (Hodgkin, 2000; Jain, 2013). Ingestion of yeast can be microscopically 
monitored over time using fluorescently marked C. albicans (Jain, 2013), confirming that 
accumulation of fungi is the likely cause of intestinal distension. 
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These disease markers can be used to study the progression of disease, while survival assays 
provide a quantitative measure of disease and death. As a simple starting model, C. elegans is a 
quick and inexpensive way to study virulence of many fungal species. However, like D. 
melanogaster, the results often need to be verified in a mammalian system, like mice. 
The nematode is a convenient model especially to study innate immunity since facets of its 
innate immune system are conserved in humans (Jain, 2013; Jain et al., 2009) and host genes 
can be easily modulated via RNAi (Kim and Rossi, 2008). Furthermore, infections do not 
require handling of animals and, therefore, can be performed in a high throughput fashion. 
Another advantage is that worms can be frozen (indefinitely) and thus do not require 
maintenance of live cultures. 
Nematodes, however, cannot be propagated at the human body temperature of 37° C. 
Therefore, the larvae of the greater wax moth Galleria mellonella are used to study virulence at 
37° C. Specifically, the virulence of certain clinical isolates of C. albicans has been correlated 
between the G. mellonella infections and murine models, lending credibility to the system. In 
addition, several bacterial strains, such as Pseudomonas aeruginosa, have been tested in the 
moth system. In contrast to other readily available, inexpensive systems, like D. melanogaster 
and C. elegans, G. mellonella has to be tediously injected one at a time and its genome has not 
been sequenced, which makes knockouts and other genetic manipulations more difficult 
(Brennan, 2002). 
3. Ex Vivo Systems 
Ex vivo systems for studying fungal infections include phagocytes in culture and tissue 
explants, as shown in Figure 2. Phagocytes are our primary defense against fungal pathogens. 
Macrophages and neutrophils play a central role in antifungal immunity by ingesting and killing 
pathogens (Lo, 1997; Lorenz and Fink, 2001; Rubin-Bejerano et al., 2003; Wheeler and Fink, 
2006). They are also responsible for initiating adaptive immune responses. 
Cultured macrophages can include both primary and immortalized cells. Immortalized cell 
lines such as the RAW264.7 and J774 are robust and can withstand harsh treatments such as 
trypsinization and scraping while still proliferating. Immortalized macrophages have been 
instrumental in uncovering aspects of Candida virulence such as hyphae formation, 
extracellular lipase, and proteinase production (Németh, 2013). However, the multiple passages 
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and harsh growth and handling conditions of immortalized macrophages specifically select 
them to be more robust at the expense of other properties that might be important for immunity. 
Therefore, primary macrophages are considered better than immortalized macrophages even 
though they are more difficult to extract and maintain (Németh, 2013). 
Németh, et al. infected both immortalized murine macrophage and primary human 
macrophage hosts with Candida parapsilosisis in the paper “Characterization of Virulence 
Properties in the C. parapsilosis Sensu Lato Species” (Németh, 2013). The fungi exhibited 
varying degrees of virulence when exposed to each type of macrophage (Németh, 2013). C. 
parapsilosis exhibited the highest resistance to killing by primary human macrophages, 
compared to C. orthopsilosis and C. metapsilosis. However, this difference was not reflected in 
the murine virulence model. In spite of these differences, cultured cell lines are useful and can 
complement live, whole-animal studies. 
Transcriptional profiling of C. albicans within phagosomes has been performed (Thewes, 
2007). Strains have been shown to quickly adapt and alter their transcriptional profile in many 
circumstances related to infection, such as response to stress, iron deprivation, and interaction 
with macrophages. In order to understand Candida infection, Thewes, et al. used in vivo and ex 
vivo techniques to understand the genes associated with infection in parenchymal organs (e.g., 
liver). For example, an ex vivo tissue explant of porcine liver-infected tissue was shown to 
mimic murine model of in vivo infection (Thewes, 2007). Candida albicans was directly 
injected into both mice and pig livers. Ex vivo tissue explants from both exhibited a similar 
extent of deep tissue invasion (Thewes, 2007). Excised murine vaginal mucosal tissue is also 
used as a substrate to study vaginal infections (Harriott et al., 2010). These ex vivo systems 
provide a simple and rapid method for optimizing conditions prior to in vivo assays (Fazly et al., 
2013). 
4. In Vitro Systems 
Viewing a fungal phenotype on an agar plate is a “host-free” method to study fungal 
virulence. For example, C. albicans mutants such as efg1−/− and cph1−/− showed reduced 
hyphal growth on agar media, and the double knockout efg1−/− cph1−/− does not form hyphae 
under most in vitro conditions. This double knockout mutant was later shown to be avirulent in 
a murine model, which linked hyphal growth and virulence (Lo, 1997). Since then, many 
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mutants with defects in dimorphic transition have been shown to be attenuated in virulence. 
This efg1−/− cph1−/− double mutant has been used extensively to validate other host models 
(Brothers, 2011; Jain, 2013). 
Chemical sensitivity in vitro can be used as a proxy for pathways that are important in vivo. 
Fungal response to important aspects of the human innate immune system such as reactive 
oxygen species can be mimicked in vitro using menadione and hydrogen peroxide (Homann, 
2009). Cell wall stressors such as sodium dodecyl sulfate (SDS), caffeine, and calcofluor 
(Homann, 2009) have been used in vitro to study the effects on the cell wall. Since human cells 
do not possess cell walls, they are good targets for drugs, like capsofungin (Homann, 2009). 
Other drug sensitivity assays can be modeled in vitro by plating fungi on drug-infused plates 
(Homann, 2009). The role of metals can be mimicked in vitro by using scavengers or chelators 
in vitro. For example, the C. albicans transcription factor Hap43 is activated by iron deficiency 
in vivo (Hsu et al., 2011) and is also required for growth upon iron-deprivation in vitro (Baek et 
al., 2008; Homann, 2009; Hsu et al., 2011). Hap43 also regulates virulence, and mice infected 
with hap43−/− strains showed attenuated virulence (Baek et al., 2008). The pathways regulating 
iron homeostasis are complicated, but in vitro techniques may be used to fine tune regulatory 
networks. 
Biofilm formation is a virulence determinant that is well suited to study in a host-free 
environment. Biofilms are typically made up of multiple microbial communities that stick to 
each other and are an abiotic surface (Hogan et al., 2004; O'Toole et al., 2000). The microbes 
secrete extracellular materials (Chandra, 2001) and are important in the context of infection 
because they are drug resistant. For example, C. albicans is thought to gain access to the 
bloodstream via plastic devices such as central lines, catheters, or other implanted devices. The 
mortality rate for patients with catheter-related BSI is approximately 41 percent (Chandra, 
2001). 
Formation of biofilm proceeds in three phases: the early phase where the fungal communities 
attach to the surface, grow, and aggregate; the intermediate phase where the extracellular matrix, a 
predominantly noncellular material, covers fungal microcolonies and is secreted into the milieu 
(Chandra, 2001); (C. albicans also transition into the hyphal form); finally, during the 
maturation phase, the extracellular material grows and planktonic yeast cells bud off and 
disseminate. 
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In vitro models can also be used to study reconstituted epithelial cells in order to model 
human infection (Figure 2). The role of certain virulence-related genes in fungal infection can 
first be modeled in vitro on reconstituted epithelial cells before using more expensive in vivo 
models. For example, the secreted aspartyl proteinases (SAP) of C. albicans have been linked to 
virulence in mucosal infection in clinical isolates of patients with chronic vaginitis (Schaller, 
2003). This family of 10 enzymes was first studied using reconstituted vaginal epithelial cells in 
order to link them to epithelial damage that occurs during disease. The 10 SAP genes are 
differentially expressed during infection. Specifically, SAP1, SAP6, SAP9, and SAP10 showed a 
stronger signal in conjunction with mucosal lesions (Schaller, 2003). These SAP genes showed 
strong signals in both in vitro models as well as in vivo samples from patients with vaginal 
infections. These lesions showed severe damage in the epithelial cells including: edema, 
vacuolization, and detachment of keratinocytes. Differential SAP expression has also been 
linked to “thrush” infections (Schaller, 2003). Despite this, they are not identical to those 
present in vaginal infections (Schaller, 2003). 
In vitro systems are extensively used to study fungal virulence to get mechanistic clues, but 
often have to be validated in an animal model to account for the complex biology in the host 
environment. Each of these systems is used to study Candida with the hope of finding better 
methods to treat infections.  
5. Conclusions 
Several models, including in vivo, ex vivo, or in vitro systems, have been used to study fungal 
disease. All models have limitations but are useful for generating testable hypotheses. The key 
is to choose a simple model that can fully address the scientific question being addressed, yet 
not so simple that the complex and interesting biology is ignored. For example, biofilms and 
certain drug sensitivities’ assays can be first performed in vitro, but then must be verified in 
vivo. Simple and inexpensive systems such as C. elegans and D. melanogaster can unveil the 
building blocks for infection, which can then be followed up in mammalian systems. 
Opportunistic fungal infections are increasing in the United States and around the world. It is 
important that the host system chosen have implications for furthering the knowledge on 
human-pathogen interactions. 
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Appendix A: Results of the Initial Screen Designed to Find Mutants that 
Show an Exaggerated Response to Filastatin 
This table shows the compilation of the 233 mutants from the first screen. FAD3 and 
ORF19.1239 were the only two that showed an increase in adhesion (highlighted in the table). 
 
Table 1: List of mutants pulled out of the initial screen 
ORF19.1797 LIP1 LIP10 ORF19.5352 ORF19.1643 ORF19.2446 ORF19.6318 CUP9 
ORF19.1162 LSC2 ORF19.3290 IFF6 SPR1 ZCF24 ORF19.4678 ORF19.4843 
ORF19.376 SOD6 ORF19.3335 ORF19.4104 DCK1 STE13 SAP3 MNT4 
LIP6 ORF19.5547 ORF19.2850 RGS2 SCW4 ZRT1 IFD3 ORF19.3418 
ORF19.3611 ORF19.268 PPZ1 STE2 ORF19.2703 CTA9 ORF19.7033 ORF19.7196 
ORF19.899 ORF19.2838 ORF19.3874 ORF19.4680 PIN4 YPT7 SIZ1 ORF19.3799 
ORF19.100 ORF19.305 ZCF2 HYR3 ARO80 MNN22 YPS7 ORF19.6660 
ORF19.215 PRM1 ORF19.2315 ORF19.6348 ORF19.2605 ORF19.3029 ORF19.3453 ORF19.7305 
CDG1 SAP8 PCL2 ORF19.557 ORF19.3049 ORF19.7370 CRZ1 RFG1  
OPT4 ORF19.255 ORF19.419 KAR3 ORF19.2781 ORF19.3060 ORF19.3488 ORF19.6693 
ORF19.6238 ORF19.7516 ORF19.13064 KIC1 RAD18 ORF19.7554 WOR2 ORF19.6245 
IFA14 ORF19.192 ORF19.433 SIN3 KAR4 ORF19.3854 ORF19.6293 ORF19.6678 
HET1 ORF19.7590 ORF19.50 ORF19.194 CHT2 CAG1 ORF19.4182 ORF19.4292 
ORF19.6607 ORF19.8009 ORF19.95 ORF19.199 MUC1 HSL1 ORF19.5892 UGA32 
ORF19.5129 ECM14 ORF19.449 BCR1 APM1 ZCF27 ORF19.7381 PIKALPHA 
ORF19.698 PGA18 ADP1 ORF19.641 PEX4 ORF19.4350 OPT6 SSU81 
OSH3 MNT1 ORF19.2265 TYE7 GRR1 ULP2 KTR4 ORF19.4972 
ARL3 ORF19.1573 ORF19.1718 ORF19.2063 ORF19.3982 SGT1 FET3 ORF19.4376 
TOS1 ORF19.1576 ORF19.2336 GPA2 PRC2 SWI4 ORF19.4844 ORF19.7086 
ORF19.1173 ORF19.1567 ARF3 PDR6 ORF19.4412 CUP2 ORF19.7096 SSK2 
SAP7 SAP98 ORF19.1185 YEA4 ORF19.5068 YCP4 MEC3 PTC7 
ORF19.757 ORF19.872 CPH2 ORF19.1392 IFA21 ORF19.5291 PEP7 MBP1 
ORF19.1219 ORF19.1397 ORF19.1577 KIP2 ENA21 LRO1 ORF19.6526 OCH1 
ORF19.782 CHK1 CFL2 ORF19.1411 ERG5 ORF19.5326 STE23 SAP1 
ORF19.783 ORF19.3615 KEX2 ORF19.6506 FGR17 RAX1 CIS2 ORF19.6553 
ORF19.5247 ECM7 ORF19.5975 ORF19.6802 GAL4 DUR35 IFD6 FAD3 
ZCF30 GLO3 ORF19.5644 ORF19.5813 ORF19.5593 SNQ2 ORF19.6802 ORF19.1239 
PST3 ECM17 ORF19.5651 RHB1 RBT4 RIM101 AXL1 IFF4 
FGR27 TUS1 CLB4 ORF19.7304 FRP1 TOM1 PGA13 ORF19.6653 
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Appendix B: Results of the Second Screen Designed to Find Targets that 
Are Blind to the Addition of Filastatin 
Table 1 and Table 2 present the results of the second screen. The characterization of each 
mutant has been provided from the Candida Genome Database.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Mutants from the Second Screen that normally adhere more than wild type 
Adheres More Than Wild Type 
PRN4 protein with similarity to pirins, flow model biofilm repressed 
CSA2 
Extracellular-associated protein; repressed by Rim101 at pH 8; regulated by 
Tsa1, Tsa1B in minimal media at 37 deg; induced by ketoconazole, nitric oxide, 
Hap43; required for normal RPMI biofilm formation; Bcr1 induced in RPMI 
ORF19.3919 RNI-like superfamily domain-containing protein; early-stage flow model biofilm induced; Spider biofilm induced 
LIP2 
Secreted lipase; member of a differentially expressed lipase gene family; 
expressed in alimentary tract, but not oral tissue, during mouse oral infection; 
may have a role in nutrition and/or in creating an acidic microenvironment 
RBT5 
GPI-linked cell wall protein; hemoglobin utilization; Rfg1, Rim101, Tbf1, Fe 
regulated; Sfu1, Hog1, Tup1, serum, alkaline pH, antifungal drugs, geldamycin 
repressed; Hap43 induced; required for RPMI biofilms; Spider biofilm induced 
HAK1 
Putative potassium transporter; similar to Schwanniomyces occidentalis Hak1p; 
amphotericin B induced; induced upon phagocytosis by macrophage; Hap43-
repressed; rat catheter biofilm repressed 
HET1 Putative sphingolipid transfer protein; involved in localization of glucosylceramide which is important for virulence; Spider biofilm repressed 
ORF19.6637 Predicted glycosyl hydrolase; hypoxia induced; flow model biofilm induced 
6 
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13 
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Figure 1: Two Pathways Represented in Second Screen. This 
figure provides a key for the tables as well. 
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HEX1 
Beta-N-acetylhexosaminidase/chitobiase, highly glycosylated enzyme that is 
secreted to the periplasm and culture medium; required for full virulence; may 
have role in carbon or nitrogen scavenging; possibly an essential gene (UAU1 
method) 
NPR2 Putative urea transporter; induced during infection of murine kidney, compared to growth in vitro; has murine homolog 
ORF19.587 Ortholog(s) have transcription export complex localization 
ORF19.649  Uncharacterized 
CFL11 
Protein similar to ferric reductase Fre10p; flucytosine repressed; possibly 
adherence-induced; possibly an essential gene, disruptants not obtained by 
UAU1 method; rat catheter biofilm repressed 
ORF19.2726 Putative plasma membrane protein; Plc1-regulated; Spider biofilm induced 
HYR1 
GPI-anchored hyphal cell wall protein; macrophage-induced; repressed by 
neutrophils; resistance to killing by neutrophils, azoles; regulated by Rfg1, Efg1, 
Nrg1, Tup1, Cyr1, Bcr1, Hap43; Spider and flow model biofilm induced 
 
Table 2: Mutants from Second Screen that normally adhere less than wild type 
Adheres Less Than Wild Type 
ORF19.380 Protein of unknown function; induced by alpha pheromone in SpiderM medium 
BTA1 Betaine lipid synthase  
ORF19.1365 Putative monooxygenase; mutation confers hypersensitivity to toxic ergosterol analog; constitutive expression independent of MTL or white-opaque status 
HWP2 
GPI-anchored, glycosylated cell wall protein; required for biofilm formation, adhesion, 
filamentous growth on some media; expressed in hyphae; mutant delayed in virulence; 
regulated by Efg1, Tup1; similar to Hwp1 and Rbt1 domains 
MTS1 
Sphingolipid C9-methyltransferase; catalyzes methylation of the 9th carbon in the long chain 
base component of glucosylceramides; glucosylceramide biosynthesis is important for 
virulence; Spider biofilm repressed 
FLO9 
Putative adhesin-like cell wall mannoprotein; repressed during the mating process; mutation 
confers hypersensitivity to toxic ergosterol analog; decreased transcription is observed upon 
fluphenazine treatment 
ORF19.5449 Predicted integral membrane protein; Spider biofilm induced 
PGA10 
GPI anchored membrane protein; utilization of hemin and hemoglobin for Fe in host; 
Rim101 at ph8/hypoxia/ketoconazole/ciclopirox/hypha-induced; required for RPMI biofilm 
formation, Bcr1-induced in a/a biofilm; rat catheter biofilm repressed 
KRE5 
UDP-glucose:glycoprotein glucosyltransferase; 1,6-beta-D-glucan biosynthesis, hyphal 
growth, virulence in mouse IV model; partially complements S. cerevisiae kre5 mutant 
defects; flow biofilm repressed, Bcr1-repressed in RPMI a/a biofilms 
ORF19.2484 Has domain(s) with predicted peptidase activity and role in proteolysis 
GZF3 
GATA-type transcription factor; oxidative stress-induced via Cap1; mutant has abnormal 
colony morphology and altered sensitivity to fluconazole, LiCl, and copper; Spider biofilm 
induced 
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ORF19.3108 Putative DNA repair methyltransferase; induced by nitric oxide independent of Yhb1; Spider biofilm induced 
ORF19.3226 Ortholog(s) have role in intracellular sterol transport and extracellular region, fungal-type vacuole lumen localization 
HYR4 Putative GPI-anchored adhesin-like protein; Rim101-repressed; constitutive expression independent of MTL or white-opaque status 
ORF19.3404 Protein of unknown function; transcription repressed by fluphenazine treatment 
ORF19.3763 Has domain(s) with predicted serine-type endopeptidase activity and integral to membrane localization 
GYP1 Putative Cis-golgi GTPase-activating protein; transcript regulated by Nrg1, Mig1, and Tup1 
KIS1 
Snf1p complex scaffold protein; similar to S. cerevisiae Gal83p and Sip2p with regions of 
similarity to Sip1p (ASC and KIS domain); interacts with Snf4p; mutants are hypersensitive 
to caspofungin and hydrogen peroxide; Hap43p-repressed gene 
ORF19.4195 
Ortholog of C. dubliniensis CD36 : Cd36_60540, C. parapsilosis CDC317 : 
CPAR2_602830, Candida tenuis NRRL Y-1498 : CANTEDRAFT_108530 and 
Debaryomyces hansenii CBS767 : DEHA2F15532g 
CAS5 
Transcription factor; cell wall damage response; required for adherence, response/resistance 
to caspofungin; repressed in core stress response; mutants have reduced CFU in mice, hyphal 
defect in C. elegans infection; Spider biofilm induced 
ORF19.4805 Putative membrane protein; induced by alpha pheromone in SpiderM medium; Hap43-induced gene; Spider biofilm induced 
IFF11  Secreted protein required for normal cell wall structure and for virulence; member of the IFF family; Hap43p-repressed gene 
ORF19.5406  Predicted plasma membrane associated protein phosphatase; required for normal filamentous growth; mRNA binds She3 and is localized to hyphal tips (1)  
PTC7 Protein phosphatase, type 2C; has S/T phosphatase activity, Mn2+/Mg2+ dependent; predicted membrane-spanning segment and mitochondrion-targeting signal 
*The descriptions of these genes were found on the Candida Genome Database 
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Appendix C: Another View at the Interaction Assay Results 
The interaction assay between Filastatin and Hemoglobin shows a decrease in adhesion when 
Filastatin alone is added, and an increase in adhesion when only Hemoglobin is added. 
Additionally, when the two are added in equal concentrations, the results show the level of 
adhesion is not simply the individual effect of each, but some interaction. However, this result 
alone does not prove what the interaction is. 
 
 
Figure 1: Another View of the Interaction Assay. This graph shows that when the same concentration of 
both Filastatin and Hemoglobin are added, the results are not simply additive, indicating an interaction. 
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Appendix D: Summary of Results from Chapter 1 
 
Figure 1: Summary of the Results from Chapter 1, Figure Produced by R.P Rao 
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Appendix E: Results of the Statistical Analysis on the Survival Assay 
Both the Log Rank Test and the Gehan-Breslow Test were performed analyzing the differences 
between the reference strain and the clinical isolate series and within each clinical isolate series.  
 
Strains Compared Log Rank Test Gehan-Breslow Test 
SC5314-PN Series <0.0001 <0.0001 
SC5314-FH Series <0.0001 <0.0001 
PN1-PN2 0.0043 0.0068 
FH1-FH2 0.1386 0.5688 
FH1-FH3 0.8788 0.7111 
FH1-FH5 0.1655 0.0692 
FH1-FH6 0.3599 0.4255 
FH1-FH8 0.7906 1.0000 
FH2-FH3 0.0763 0.4672 
FH2-FH5 0.0010 0.0040 
FH2-FH6 0.5078 0.7770 
FH2-FH8 0.0914 0.5063 
FH3-FH5 0.2055 0.0647 
FH3-FH6 0.4300 0.6560 
FH3-FH8 0.5758 0.7297 
FH5-FH6 0.1127 0.0156 
FH5-FH8 0.9954 0.1282 
FH6-FH8 0.2918 0.5795 
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Appendix F: Phenotypic Examination of a Laboratory Tetraploid Strain 
The following figures and tables show the results of the phenotypic profile of the reference 
strain (SC5314), a laboratory generated tetraploid strain (RBY18), as well as its two parent 
strains (RBY16 and MMY304). In vivo, survival, and several in vitro assays have been 
performed on these strains, though no correlation between phenotype and ploidy could be made.    
 
 
 
Figure 1: Survival Curves for Laboratory Tetraploid Strain, RBY18, and its two diploid parents, RBY16 
and MMY304 
Table 1: Reported p values for Log Rank Test and Gehan-Breslow Tests for Survival Data of Clinical 
Isolates. Significant p values are bolded.  
Strains Compared Log Rank Test Gehan-Breslow Test 
RBY18-RBY16 0.7441 0.1032 
RBY18-MMY304 0.0517 0.1006 
RBY16-MMY304 0.0805 0.7160 
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Figure 2: Filamentation on spider media of the reference strain, SC5314. RBY18, RBY16, and MMY304 
were included in this study to make potential connections between ploidy and morphology. 
 
Figure 3: Invasion of Reference Strain, SC5314, and RBY18, RBY16, and MMY304. 
SC5314 RBY18 
RBY16 MMY304 
SC5314 RBY18 
RBY16 MMY304 
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Figure 4: Heat Map Indicating Relative Responses to Each Stressor. Black indicated more resistance and 
white more sensitivity. The reference strain, SC5314, was plated for comparison purposes as well.  
 
 
 
Figure 4: Relative Adhesion of all strains tested compared to the reference strain SC5314. This table 
includes a lab tetraploid, RBY18, and its two diploid parents, RBY16 and MMY304. 
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Appendix G: Requirements for Graduation 
Academic  
 
M.S. Requirements 
 
                                                   Required credits                                      Received 
 
BBT courses                                    3 Classes                                             4 Classes 
  
 
Advanced Genetics and Cellular Biology…………………………………....A 
Experimental Design and Statistics…………………………………………..A 
Medical Device Regulation………………………………………………......A 
Special Topics: Animal Cell Culture Technology…………………………....B 
 
BB501 Seminar                        Every semester                                              !        
 
Journal Club                                         1                                                         1 
 
Ethics  1                                                        1 
 
Research Credits                           At least 6                                                 19 
 
Manuscript                                No Requirement                          1 Review Published 
 
Pathogens 2014, 3(3), 549-562; doi:10.3390/pathogens3030549 
 
Thesis    
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